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Introduction 
     Abstract:  
     The neurovascular unit (NVU) is an important structural component in the central 
nervous system (CNS). The NVU consists of multiple cell types that include endothelial 
cells, pericytes, astrocytes, and others, working collectively as a restrictive interface 
between blood and neural tissue within the CNS. The NVU functions to transport 
nutrients, ions, and other substances to and from the blood to maintain homeostasis 
within the neural cell microenvironment. The NVU is responsible for the regulation of 
nutrient and ion transport from the blood as neurons require a fastidious supply of 
nutrients and ions in order to function properly. It is also important to regulate the neural 
cell microenvironment as many molecules and substrates in blood serum can be 
detrimental to neural function. This neural dysfunction may, in turn, lead to CNS 
complications. A dysfunctional NVU is associated with many disease states, including 
Alzheimer’s, ALS, strokes, multiple sclerosis, epilepsy, and glioblastomas. These disease 
states are linked to, but not limited to, deregulation of nutrient transport, NVU 
inflammation and leakage of blood constituents into the neural environment, 
downregulation of the basal lamina, reduced efficacy and downregulation of ATP-
binding cassette (ABC) transporters, and downregulation of tight junction proteins. 
Therefore, it is important that the NVU possesses mechanisms for which it can restrict 
passage of detrimental substances into the CNS. The endothelial cell is a principal 
barrier-forming cell of the NVU because of its direct contact with the blood, its 
intercellular tight junctions, biotransforming enzymes, and asymmetric distribution of 
active and carrier-mediated transporters. These properties are important in the separation 
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of blood from neural tissue and regulation of nutrients and ions within the neural 
environment. Maintaining and regulating these properties requires an abundant supply of 
energy, in the form of adenosine triphosphate (ATP). Therefore, endothelial cell energy 
metabolism is a critically important area of study. Cellular energy metabolism is 
considered the process of exploiting various metabolic substrates to produce ATP. Cells 
typically utilize glycolysis and oxidative phosphorylation (OXPHOS) as energy 
producing pathways to maintain cellular ATP demand. OXPHOS is considered the major 
contributor in ATP production as it produces ~ 33 molecules of ATP per glucose 
molecule, whereas glycolysis produces only two molecules of ATP per glucose molecule. 
Glycolysis is often overlooked due to this imbalance of ATP production. However, it is 
becoming more evident that glycolysis may be a primary energy producing pathway due 
to its rapid turnover rate and production of molecules that are able to be utilized as 
building blocks for cellular compartments. Cellular bioenergetics using extracellular flux 
analysis has been extensively used to study many different cell types such as tumor, 
immune, and stem cells, but little is known about the energy producing pathways of brain 
endothelial cells. Here, we characterize the bioenergetics of human brain microvascular 
endothelial cells by using human brain microvascular endothelial hCMEC/D3 cells as a 
model. hCMEC/D3 cell bioenergetic properties were characterized by investigating 
metabolite preference and the effects of various metabolic inhibitors on extracellular 
acidification and OXPHOS rates. Glycolysis and OXPHOS can be quantitatively 
measured by using extracellular flux analysis. Using sensitive probes, extracellular flux 
analysis can measure extracellular acidification and oxygen consumption to quantify 
glycolytic and OXPHOS rates, respectively. In this study, we show that these cells utilize 
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glycolysis as a primary metabolic pathway and glucose as the preferred metabolite. 
Although glucose is the primary metabolite hCMEC/D3 cells utilize, they are able to 
maintain ATP production by utilizing pyruvate and glutamine as well via OXPHOS. 
Using monocarboxylate transporter 1 (MCT1), mitochondrial pyruvate carrier (MPC), 
glutaminase (GLS), and glucose transporter 1 (GLUT1) inhibitors, we were able to 
explore the metabolic flexibility of hCMEC/D3 cells. Nutrient transport inhibition 
significantly altered glycolytic and oxidative properties of hCMEC/D3 cells. These 
findings reveal a basic understanding of brain endothelial cell energy production and 
metabolism. This data may also contribute to our understanding of altered brain 
endothelial cell function in disease or under conditions of active angiogenesis during 
development or tumorigenesis. Further understanding of altered brain endothelial cell 
energy metabolism in a diseased state can allow for the development of therapeutics that 
target these altered pathways. 
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Chapter 1: Background 
     Endothelial cells, astrocytes, pericytes, and neurons cooperate together to create a 
unique barrier between neural tissue of the central nervous system (CNS) and 
constituents of the blood [1–13]. These cell types, that form an intricate interface between 
the CNS and its vasculature, are collectively named the neurovascular unit (NVU) 
[3,6,7,10–12,14–16]. The NVU is also commonly termed the blood-brain barrier. 
Animals with a developed CNS possess an NVU [2]. Through decreased paracellular 
transport and active efflux, the NVU provides a stable environment for neural function by 
effectively separating blood and neural tissue. The NVU is also important in maintaining 
neural tissue environment by utilizing nutrient and ion transporters to sustain adequate 
levels of molecules, nutrients, and ions within the CNS tissue.  
     Brain endothelial cells are a key component of NVU integrity and function due to 
their direct contact with blood, restricted paracellular transport, biotransforming enzymes, 
expression of ATP binding cassette (ABC) efflux transporters, and asymmetric 
distribution of ion and nutrient transporters. These properties are important as normal 
neural function requires a very particular, and consistent, composition of nutrients and 
ions within the neural environment [2]. It has been observed that ion and nutrient 
composition, such as amino acid, potassium, and calcium levels, remain consistent in the 
CNS tissue even when blood serum concentrations fluctuate [17]. Some blood 
constituents can be detrimental to neural function, such as the amino acid glutamate [3], 
therefore it is important to restrain some substances from getting into the CNS tissue. 
Proteins, hormones, and ions within blood serum can disrupt normal neural function by 
acting as neurotransmitters, affecting transcription and intercellular signaling, and 
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activating voltage gated ion channels, respectively. Brain endothelial cells are an 
important component in regulating harmful blood constituents from neural tissue due to 
restricted permeability of many small molecules and water-soluble substances via tight 
junctions [18–21]. Lipophilic and xenobiotic substances are restricted from crossing into 
the CNS through the use of active efflux transporters [2,22–24]. 
Tight Junctions 
     Claudins, VE-cadherin, junction adherence molecules, and occludins interact with 
cytosolic catenins, zonula occludens, and the cellular actin cytoskeleton to create a highly 
restrictive junction between endothelial cells [20,21]. This restrictive junction is termed 
the “tight junction”. Tight junctions between endothelial cells considerably decrease 
paracellular transport of hydrophilic and small molecules from the blood into the CNS 
[15,18–21]. Claudin-1, -3, -5, and -12 are tight junction proteins that are expressed in 
brain endothelial cells and are essential in restricting paracellular transport of various 
small molecules [11,18,20,25,26]. Claudin-5 is said to be the predominant junction-
forming protein and is important in the regulation of small molecule transport between 
cells [19,27]. Compared to endothelial cells within other tissues, brain endothelial cells 
have shown to express 600-fold higher amount of claudin-5 than claudin-3 [26]. Claudin-
3 and -5 are essential for maintaining tight junction integrity as experiments show the 
genetic loss of either protein, in mice models, leads to a compromised and leaky NVU 
and death [19]. It has also been revealed that disruption of tight junctions, via edema 
formation in the brain, was associated with a decrease in intracellular ATP generation in 
mice brain microvascular endothelial cells [28]. ATP repletion has also found to have a 
regenerative effect as it allows zonula occludens to associate more with tight junction 
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proteins, rather than the cellular cytoskeleton, in MDCK epithelial cells [29]. Due to the 
restricted paracellular permeability of brain endothelial cells, many molecules, nutrients, 
and ions in blood need to be transported into the CNS environment by alternative 
transport mechanisms, such as transcellular transport.  
Endothelial Cell Transport 
     Transcellular transport mechanisms include diffusion, ion channels, receptor mediated 
and adsorptive transcytosis, and use of either passive or active membrane transporters. 
Membrane transport proteins such as the glucose transporter, GLUT1, and transporters of 
the solute carrier (SLC) family are essential in providing the CNS with the needed 
nutrients and amino acids from the blood in order to function properly [2,30]. The CNS is 
known to consume a large supply of glucose, the main energy source for the brain, to 
support its high energy needs [31]. Of the solute carriers, GLUT1 is one of the highest 
expressed nutrient transporter in brain endothelial cells [32,33]. Another important SLC 
transporter expressed in brain endothelial cells is MCT1. MCT1 allows transportation of 
lactate, pyruvate, and ketone bodies as alternative fuels when glucose is limited [34]. 
Transport of nutrients and ions is also achieved by the asymmetrical distribution of these 
transporters in brain endothelial cells between the lumen of the vasculature and the CNS 
tissue [2,35]. GLUT1 and MCT1 are expressed on both luminal and abluminal aspects of 
the brain endothelial cell membrane [2,33]. Many amino acid carriers are located on the 
abluminal side of endothelial cells, allowing for high regulation of the neural 
environment [36]. Amino acid regulation is important as the CNS environment contains a 
very limited amount of amino acids compared to blood serum [2]. Expression of SLCs 
and ion transporters on luminal, abluminal, or both sides of brain endothelial cells allows 
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for the transport of nutrients, nucleotides, amino acids, ions, and other molecules into or 
out of the CNS tissue to support neuronal function. Ion transporters, such as Na+/K+ 
ATPase require ATP for active transport of ions into and out of the neural environment 
[28,36]. Nutrient transport also allows endothelial cells to utilize these nutrients to 
generate ATP to perform cellular functions and maintain NVU integrity. ATP generation 
from nutrient metabolism can be used to maintain tight junction integrity, for active 
efflux of harmful molecules, and for maintaining adequate ion concentrations in the CNS 
environment via Ca2+- and Na+/K+-ATPases [28,29]. 
Active efflux 
     Active efflux of lipophilic, neurotoxic, and xenobiotic molecules further complements 
the restrictive properties of brain endothelial cells. Efflux transporters are considered a 
family of ATP-binding cassette (ABC) transporters. The primary ABC transporters of the 
NVU are Multidrug Resistance-associated Proteins (MRPs), P-glycoproteins (Pgp), and 
Breast Cancer Resistance Proteins (BRCP) [2,22]. These efflux transporters have made it 
difficult to develop small molecule drugs to treat CNS diseases as they are rapidly 
exported back out into the blood. As these transporters function via ATP hydrolysis, 
cellular ATP generation is important to allow consistent efflux of harmful molecules 
from the CNS. 
     Cells require energy, in the form of ATP, in order to perform many different functions 
such as cell division, signaling cascades, enzyme activation, transcytosis, tight junction 
maintenance, active efflux, and active transport of nutrients and ions. Cells are able to 
utilize various metabolites, such as glucose, glutamine, pyruvate, fatty acids, ketone 
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bodies, and amino acids to generate ATP through several metabolic pathways. Two 
primary energy producing pathways cells exploit are glycolysis and OXPHOS.  
Glycolysis 
     Glycolysis involves the conversion of one glucose molecule into two molecules of 
pyruvate, which then may be converted to lactate [37,38]. The first and third steps of 
glycolysis consume two molecules of ATP to convert glucose into glucose-6-phosphate 
and fructose-6-phosphate into fructose-1,6-bisphosphate, respectively [39]. Fructose-1,6-
bisphosphate is then converted into two glyceraldehyde-3-phosphate molecules, which 
are subsequently converted into two pyruvate molecules via multiple enzymatic steps 
[38,39]. From this process, four ATP molecules are produced, yielding a total of two 
molecules of ATP produced from one molecule of glucose [39]. Pyruvate can be 
converted into lactate, by lactate dehydrogenase, and exported into the extracellular 
environment, along with a hydrogen ion, through monocarboxylate transporters (MCTs) 
[8,40–42]. The process of which glucose is subsequently converted into lactate is 
considered glycolysis.  
OXPHOS 
     Pyruvate produced from glycolysis, though, is primarily thought to be transported into 
the mitochondria, via mitochondrial pyruvate carrier (MPC), and converted into acetyl-
CoA, which enters the tricarboxylic acid (TCA) cycle [43]. The TCA cycle converts 
acetyl-CoA into oxaloacetate, using multiple enzymatic reactions, and produces three 
NADH molecules and one FADH2 molecule. Other molecules, such as glutamine, can 
also fuel the TCA cycle through multiple enzymatic steps where glutamine is converted 
into glutamate, via glutaminase (GLS), which is then converted into alpha-ketoglutarate, 
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a TCA cycle intermediate [44,45,107,111]. NADH and FADH2 participate in the electron 
transport chain (ETC) to carry and donate electrons and create a proton gradient between 
the intermembrane space and the mitochondrial matrix [46]. The electrical-chemical 
gradient, from the transport of protons, is then exploited by ATP synthase to produce 
~33.45 molecules of ATP (per glucose molecule) [47]. The electrons participating in the 
ETC then use oxygen as a final electron acceptor and H2O is produced. 
     Cells are able to utilize various metabolites to generate ATP through either glycolysis 
or OXPHOS, such as glucose, pyruvate, glutamine, lactate, and fatty acids [48–53]. 
Numerous metabolic pathways have gained attention as targets for various diseases, 
especially for different cancer types. Such pathways include glycolysis, lactate export 
and/or import, glutamine metabolism, and mitochondrial transport of pyruvate. Targeting 
glucose metabolism by inhibiting GLUT1, a primary glucose transporter, has shown to 
decrease cell proliferation in various cancer types [54,55], as many tumors and cancerous 
cells consume large amounts of glucose to proliferate rapidly [56,57]. Depending on the 
metabolic state of the cells, targeting lactate and pyruvate metabolism by inhibiting 
MCTs and MPCs have also shown to be promising treatments for various cancer types 
[41,51,58–60]. Metabolic pathways have also gained attention in immune and stem cell 
activation. It is shown that both immune cells and stem cells exhibit a change in cellular 
metabolism when in transition to an activated or quiescent state [61–64]. There have been 
extensive studies investigating the effectiveness of inhibiting bioenergetic pathways for 
treating various cancers and observing a change in the metabolic phenotype of immune 
and stem cells. However, characterizing the metabolic phenotype and studying the effects 
of inhibiting various pathways have not been studied for brain endothelial cell 
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metabolism. Studying the metabolic phenotype and the effect of disrupting glucose, 
pyruvate, or glutamine metabolism in brain endothelial cells may give insights to brain 
endothelial cell energetic characteristics and possible disease treatments involving the 
NVU dysfunction. 
     It has been estimated that the NVU is impermeable to more than 98% of small-
molecule drugs, making treatment for many neurological diseases difficult [23]. Such 
neurological conditions, including Alzheimer’s disease, stroke/ischemia, and 
glioblastomas involve tight junction break-down and a change in brain endothelial cell 
function and integrity [4,6,14,16,65,66]. Studies have shown that GLUT1 deficiencies in 
brain endothelium lead to cognitive impairments and increased permeability of the NVU 
[67,68]. Alzheimer’s disease has also shown to exhibit a decreased expression of GLUT1 
in brain endothelium [2]. Strokes and ischemia involve the release of pro-inflammatory 
cytokines, VEGF, and nitric oxide, which leads to tight junction disruption, angiogenesis, 
and increased NVU permeability [4]. 
     Changes in brain endothelial cell function and integrity can be accompanied by 
changes in cellular energy demand and metabolism. Barrier breakdown, changes in 
nutrient transport, such as decreased expression or deficiency of GLUT1, changes in 
active efflux of detrimental molecules, and disrupted angiogenesis can all require a 
change in ATP demand. There have been many studies regarding structural, 
transcriptional, and proteomic components of brain endothelial cells involved in NVU 
integrity and disruption. However, the bioenergetic characteristics of brain endothelial 
cells have not been investigated. It is imperative then, to investigate brain endothelial cell 
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bioenergetics to understand differences in energetic needs and metabolic processes, both 
in healthy and diseased states.  
     Studying cellular bioenergetics of brain endothelial cells can be achieved through the 
use of extracellular flux analysis. Measuring oxygen consumption rates (OCRs) and 
acidification of media, in real-time, in conjunction with various compound injections that 
alter or inhibit metabolic pathways, can reveal insights toward brain endothelial cell 
bioenergetics. These real-time measurements can be quantified and used to characterize 
energy producing pathways and metabolic flexibility of brain endothelial cells. 
Glycolysis is associated with the production of lactate, which is then exported from the 
cytosol with a proton via MCTs. Therefore, in order to quantify glycolytic rates, 
extracellular acidification measurements can be used. If pyruvate is not converted into 
lactate and exported, it then enters the TCA cycle and fuels OXPHOS, hence, oxygen 
consumption measurements can then be used to measure mitochondrial respiration rates.  
     This study provides a unique insight to the metabolic properties and bioenergetics of 
immortalized, as well as primary, human capillary microvascular endothelial cells. The 
immortalized hCMEC/D3 cell line has been extensively characterized and represents a 
promising NVU model in vitro.  Therefore, through the use of the Seahorse XFe96 
Bioanalyzer, OCRs, extracellular acidification rates (ECAR), and proton efflux rates 
(PER) of hCMEC/D3 cells were recorded, in real-time, and quantified to calculate 
glycolytic and mitochondrial characteristics. Using these recordings, we were able to 
develop a basic understanding of the typical energetic characteristics of hCMEC/D3 cells. 
We also observed the effects of MCT, MPC, GLS, and GLUT1 inhibition on energy 
production to observe the metabolic flexibility and ability to utilize different metabolites 
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of hCMEC/D3 cells. Glucose, pyruvate, and glutamine preference and utilization was 
also studied in hCMEC/D3 cells. 
     Endothelial cells in other tissues of the body contain very little mitochondria and 
exploit glycolysis as a primary source of ATP [37,69,70]. However, brain endothelial 
cells have approximately double the number of mitochondria than other tissues [37,70]. 
This phenomenon was also observed by Oldendorf and Brown in 1976, as they detected 
that rat brain endothelial cells contained more mitochondria than skeletal muscle cells. 
This led us to hypothesize that brain endothelial cells would have a considerable high rate 
of OXPHOS to meet energy demands. Although brain endothelial cells may contain more 
mitochondria than endothelial cells of different tissues, hCMEC/D3 cells and primary 
human brain microvascular endothelial cells exhibited a primarily glycolytic mode of 
metabolism, where a majority of protons produced are from glycolysis, and relatively 
little utilization of mitochondrial respiration. This is further supported as glycolytic ATP 
production rates were higher than mitochondrial ATP production rates. 
     We then hypothesized that changing the composition of available metabolites would 
alter the metabolic phenotype of hCMEC/D3 cells. Cells were presented with glucose, 
glutamine, pyruvate, a combination of two, or all three to test the effect of metabolite 
composition on hCMEC/D3 energy production. Metabolite composition in the 
extracellular space showed to significantly alter glycolytic and mitochondrial energy 
production in cells. With glucose present, the cells favored glycolysis and little glucose 
was shunted to OXPHOS. When presented with pyruvate and/or glutamine, cells 
increased mitochondrial activity to meet energy demands. When presented with an equal 
concentration of either metabolite or a combination, the total ATP production rates of 
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hCMEC/D3 cells also remained relatively consistent, with the exception of glutamine 
alone. 
     We then hypothesized that disrupting glucose transport, pyruvate transport into the 
mitochondria, conversion of glutamine into glutamate, or a combination of two or all 
three would alter energy production in hCMEC/D3 cells. To disrupt glucose and pyruvate 
transport, we utilized small molecule inhibitors BAY876 and UK5099, respectively. 
Glutamine conversion into glutamate was inhibited by using the small molecule inhibitor 
BPTES. We also tested inhibition of MCT1 or dual inhibition of MCT1 and MCT4 via 
small molecule inhibitors AZD3965 and MD1, respectively. Disruption of glucose 
transport significantly altered glycolytic and mitochondrial energy production in 
hCMEC/D3 cells. Mitochondrial targeted disruption altered various mitochondrial 
characteristics and lactate transport did not alter hCMEC/D3 energy production. 
Chapter 2: Materials and Methods 
Cell Culture 
     hCMEC/ D3 immortalized human brain microvascular cells were purchased from 
Millipore® (Cat. No. SCC066). Primary human brain microvascular endothelial cells 
were purchased from Cell Systems® (Cat. No. ACBRI 376). 1 mL aliquots of cells in 
growth medium were prepared and stored in liquid nitrogen. Cells were thawed with, and 
cultured, in growth medium containing 45% Ham’s F10 (Gibco, Cat. No. 12390-027), 
45% alpha MEM (Gibco, Cat. No. 12561-023), 10% fetal bovine serum, and 1.74 mM L-
glutamine (Sigma, Cat. No. G 7513). The growth media was also supplemented with 0.5 
mL Gentamicin (Gibco, Cat. No. 15710-015), and 500 ng of fibroblast growth factor β. 
Cells were incubated at 37°C and 5% CO2 on rat tail collagen type I coated T75 cell 
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culture flasks. To passage cells, cells were washed with PBS and trypsin was added to the 
culture flask and cells incubated at 37°C and 5% CO2 for 3-5 minutes. Growth media was 
then added to the cell-trypsin mixture to inactivate the effects of trypsin. The cell mixture 
was then centrifuged at 1000 rpm for 5 minutes to create a cell pellet. The resulting 
supernatant was then discarded and the cell pellet was resuspended in fresh growth 
media. A hemocytometer was then used to count cells and cell density was calculated to 
reseed culture flasks. Immortalized cells were then discarded after 20 passages due to 
possibility of losing unique brain endothelial cell properties. Primary cells were discarded 
after 4-6 passages. 
Extracellular Flux Analysis 
     Extracellular flux analysis was performed using the Seahorse Xf96 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). This instrument is able to measure oxygen 
consumption, in real-time, by using sensitive fiber optic probes. These probes create a 
sealed environment in each well of a 96-well microplate to measure both oxygen levels 
and acidification of media within the wells (Figure 1). Using this technology, cells can be 
added to wells, where they would then adhere to the bottom and perform metabolism, 
consuming both oxygen, from OXPHOS, and producing lactic acid, from glycolysis. The 
probes would then measure oxygen and pH levels to later quantify respiration and 
glycolytic rates, respectively. These measurements can be taken in conjunction with 
timed injections of metabolic inhibitors in order to determine several metabolic 
characteristics, such as basal OCR, ATP coupled OCR, maximal respiration rates, non-
mitochondrial OCR, basal PER, glycolytic PER, compensatory glycolysis, glycolytic 
ATP production rates, and mitochondrial ATP production rates. Injections are achieved 
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by utilizing four injection ports surrounding the probe, labeled A-D. Injections are done 
in a step-wise manner, where port A is injected first, then ports B, C, then D. Compounds 
within injection ports can be injected at desired times and mixed in wells by agitation of 
probes moving up and down. Oxygen and pH measurements can then be done for a 
desired amount of time as well. 
16 
 
Figure 1: EXTRACELLULAR FLUX ANALYSIS CONFIGURATION AND 
ECAR/OCR CONTRIBUTIONS Extracellular flux analysis is achieved by utilizing 
sensitive optic probes, that measure changes in pH and oxygen levels of media, in a 
sealed environment where cells, adhered to the bottom of the well, perform glycolysis 
and mitochondrial respiration. Drug delivery ports surrounding the probe allow timed 
injections of various drugs to measure glycolytic and mitochondrial characteristics (Top). 
Glycolysis that leads to the conversion of pyruvate into lactic acid, which is then 
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exported, is the primary contributor to ECAR measurements. The TCA cycle and 
OXPHOS is the primary contributor to OCR measurements (Below). 
 
Day prior to assay:  
     Cells were grown to 80-100% confluency, in a T75 cell culture flask, and seeded at 
11.5 x 103 cells per well in a rat tail type I collagen coated Seahorse XFe96 Spheroid 
Microplate (Part No. 101085-004). Rat tail type I collagen was purchased from Corning 
(No. 354236). Cells incubated in the microplate for 20-24 hours at 37°C and 5% CO2 
prior to assays. A sensor cartridge was also hydrated with 200 µL of sterile water, per 
well, in a non-CO2 incubator 20-24 hours at 37°C. 
Day of Assay: 
     At least an hour prior to assay, water was replaced with 200 µL of XF calibrant in the 
sensor cartridge. After the overnight incubation period, growth media was removed by 
respiration and cells were washed twice with assay media consisting of Seahorse XF 
minimal base medium supplemented with 5.83 mM glucose, 1.5 mM glutamine, 1 mM 
pyruvate, pH adjusted to 7.4, and filtered to sterilize. For metabolite studies, an assay 
media consisting of 5 mM glucose, 5 mM glutamine, 5 mM pyruvate, a combination of 
two metabolites, or a combination of all three metabolites was used. A total of 175 µL 
assay media was then added to the wells and cells were incubated at 37°C in assay media, 
non-CO2 incubator, one hour prior to the assay. Oligomycin, trifluoromethoxy 
carbonylcyanide phenylhydrazone (FCCP), rotenone, and antimycin A, for mito stress 
test and ATP rate studies, were synthesized by the Mereddy Lab at the University of 
Minnesota, Duluth Campus. 
Mito Stress Test: 
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     1 µM oligomycin, 0.5 µM FCCP, and 0.5 µM rotenone/antimycin A were prepared, 
using assay media, and 25 µL was added to ports A, B, and C in the sensor cartridge, 
respectively, to be injected into wells at designated times. After one hour of incubation, 
the 96-well microplate was placed in the Seahorse Bioanalyzer to begin oxygen 
consumption measurements. Oligomycin, FCCP, and rotenone/antimycin A were injected 
following three measurements prior to injection (Figure 2). For measurements, three 
minutes of mixing occurred prior to three minutes of measuring. Oligomycin inhibits 
ATP synthase, FCCP uncouples the proton gradient between the inter-membrane space 
and the mitochondrial matrix, and rotenone/antimycin A inhibit complexes I/III of the 
electron transport chain. Using the differences in measurements following the injection of 
these compounds, basal, ATP coupled, maximal respiration, spare respiratory capacity, 
proton leak, and non-mtochondrial OCR values can be calculated (Figure 2). 
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Figure 2: MITO STRESS TEST PROTOCOL A representation of real-time OCR 
measurements from a mito stress test. Timed injections of oligomycin, FCCP, and 
rotenone/antimycin A inhibit ATP synthase, uncouple the proton gradient between the 
inner mitochondrial membrane and the mitochondrial matrix, and inhibit complexes I/III 
of the mitochondria, respectively. From real-time measurements and timed injections of 
these compounds, basal OCR, ATP coupled OCR, maximal respiration OCR, spare 
respiratory capacity OCR, proton leak OCR, and non-mitochondrial OCR can be 
calculated. 
 
Glycolytic Rate Assay: 
     50 mM 2-deoxyglucose (2-DG) (Agilent, No. 103344-100) and 0.5 µM 
rotenone/antimycin A were prepared, using assay media, and 25 µL was added to ports A 
and B in the sensor cartridge, respectively, to be injected into wells at designated times. 
Following one hour of incubation, assay media was removed by respiration and fresh 
assay media was added to cells. The 96-well microplate was then placed in the Seahorse 
Bioanalyzer to begin extracellular acidification measurements. Rotenone/antimycin A 
and 2-DG were injected following three measurements prior to injection (Figure 3). For 
measurements, three minutes of mixing occurred prior to three minutes of measuring. 
Using real-time ECAR measurements following injection of these compounds, basal, 
glycolytic, compensatory, and post 2-DG PER values can be calculated (Figure 3). 
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Figure 3: GLYCOLYTIC RATE ASSAY PROTOCOL A representation of real-time 
PER measurements of a glycolytic rate assay. Timed injections of rotenone/antimycin A 
and 2-DG inhibit mitochondrial complexes I/III and hexokinase, respectively. From real-
time measurements and timed injections of these compounds, basal PER, glycoPER, 
compensatory glycolyric PER, and post 2-DG acidification can be quantified. 
 
ATP Rate Assays: 
     For inhibitor assays, 50 nM BAY876 (MedChem Express, Cat. HY-100017), 10 µM 
AZD3965 (MedKoo Biosciences, Cat. 206040), 10 µM MD1 (University of Minnesota, 
Duluth Campus, Mereddy Lab), 5 µM UK5099 (MedChem Express, Cat. HY-15475), 
and 5 µM BPTES (Cayman Chemical Cat. 19284) were prepared, using assay media, and 
added to designated wells in 96 well plated for the one-hour incubation period at 37°C in 
a non-CO2 incubator. 1 µM oligomycin, 0.5 µM FCCP, and 0.5 µM rotenone/antimycin 
A were prepared, using assay media, and 25 µL was added to ports A, B, and C in the 
sensor cartridge, respectively, to be injected into wells at designated times to observe 
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respiratory and glycolytic characteristics. Following the one-hour incubation period, 
assay media was removed by respiration from each well and fresh assay media, and 
inhibitors (for inhibitor studies), was added to designated wells. The microplate was then 
immediately placed in the Seahorse bioanalyzer to begin extracellular flux analysis. 
Oligomycin was injected following six measurements. Following oligomycin injection, 
FCCP and rotenone/antimycin A were subsequently injected and allowed three 
measurements following injection (Figure 4). 
 
Figure 4: ATP RATE ASSAY PROTOCOL A modified ATP-rate assay was used to 
measure mitochondrial and glycolytic characteristics of hCMEC/D3 cells by utilizing 
real-time OCR and ECAR measurements paired with sequential injections of oligomycin, 
FCCP, and rotenone/antimycin A. Using these real-time measurements, mitochondrial 
respiration, glycolytic, and ATP production rates were quantified using calculations from 
mito stress test, glycolytic rate, and ATP production rate equations. OCR measurements 
were used to calculate basal, ATP coupled, maximal respiration, spare respiratory 
capacity, proton leak, and non-mitochondrial OCR values along with mitochondrial ATP 
production rates. ECAR measurements were used to calculate basal PER, glycolytic PER, 
compensatory glycolytic PER, and glycolytic ATP production rates. 
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Microscopy 
     A laser confocal microscope was used to image cells along with mitochondria and 
DNA. Cultured cells were taken from culture flasks by trypsinization and seeded in 35 
mm collagen coated glass bottom (No. 0) petri dishes purchased from MatTek (Part No. 
P35GCOL-0-10-C). Cells incubated at 37°C and 5% CO2 for at least 2 days and allowed 
at least one media change. 150 nM MitoTracker Red CMXRos, purchased from Cell 
Signaling, (No. 9082S) and 300 nM DAPI, purchased from Thermo Fisher (No. D1306), 
was prepared in Seahorse minimal basal medium containing 5.83 mM glucose, 1.5 mM 
glutamine, 1 mM pyruvate, and pH to 7.4. Seahorse minimal basal medium with 
supplemented metabolites was added to cells, which then incubated at 37°C and 5% CO2 
for one hour. Media was then discarded from cells and 4 mL of the MitoTracker/DAPI 
basal media solution was added to cells. Cells were then incubated at 37°C and 5% CO2 
for 15-30 minutes. Media and dyes were then discarded and cells were washed with PBS 
and fixed with cold methanol/1% acetic acid. Cells were then stored in -20°C for at least 
four hours. Methanol/acetic acid was then discarded and cells were washed with PBS 
then distilled water. Petri plates were then allowed to dry and then were imaged using the 
laser confocal microscope.  
Data Normalization and Statistical Analysis 
     To normalize OCR, ECAR, and PER values obtained from real-time measurements, 
media from wells was discarded immediately following assays, leaving ~20 μL left, and 
150 μL of cold methanol/1% acetic acid was added to wells to fix cells. Cells were then 
stored in -20°C for at least four hours. Methanol/1% acetic acid was then discarded, wells 
were washed twice with cold PBS, and plates were allowed to air-dry. A BCA protein 
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assay was then performed on the fixed cells to determine the amount of protein in each 
well. The protein amount was then used to normalize OCR, ECAR, and PER data to 10 
µg of protein. ATP production calculations were done using equations provided by 
Romero et al. (2018) [71]. For hCMEC/D3 and hMVEC comparisons, statistical analysis 
was not performed because hMVEC came from one individual. For inhibitor and 
metabolite studies, one-way ANOVA analysis paired with Tukey’s method was used to 
determine statistical significance of data between treatment groups. GraphPad by Prism 
was the software used for graph construction and statistical analysis. All experiments and 
treatment groups include a sample size of n=3. 
Chapter 3: hCMEC/D3 Cells as a Model for Bioenergetic Studies 
     hCMEC/D3 cells were chosen as a model for these experiments because of their 
similarities with primary human brain endothelial cells, ease of culturing, and 
inexpensiveness. The hCMEC/D3 cell line is extensively characterized and has shown to 
represent a promising model of the NVU for various studies. Though hCMEC/D3 do not 
express high trans-endothelial electrical resistance values [5], which is a defining 
characteristic of the NVU, there are other similarities in tight junction, efflux 
transporters, surface receptors, and solute carrier expression. A comparative study 
performed by Eigenmann et al. (2013) showed that hCMEC/D3 cells exhibit high 
expression of brain endothelial cell tight junction proteins zonula occludin-1, VE-
cadherin, and claudin-5. Furthermore, Weksler, Romero, and Couraud (2013) show that 
hCMEC/D3 cells express other brain endothelial cell markers such as CD34, CD31, 
CD40, CD105, CD144, and von Willebrand factor. hCMEC/D3 cells do not express 
CD36, which is not present in human brain endothelial cells as well. Weksler et al. 
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(2005) show that hCMEC/D3 cells exhibit similar permeability coefficients to 
hydrophilic molecules, such as sucrose and inulin, when compared to a bovine co-culture 
model. There is also decreased permeability to hydrophilic molecules when compared to 
rat brain endothelial cell lines RBE4 and GPNT. hCMEC/D3 cells express defining 
human brain endothelial ABC transporters such as P-gp, MDR1, MRPs, and BCRP 
[72,73]. Ohtsuki et al. (2013) show that hCMEC/D3 cells have similar proteomic 
expression of the transporters Na+/K+ ATPase, MCT1, and GLUT1 when compared to 
human brain microvessels. These defining characteristics of brain endothelial cells are 
maintained, in culture, until the 35th passage [72]. This allows for various experiments to 
be performed on these cells over an extended period of time. Extracellular flux analysis 
of primary human brain microvascular endothelial cells showed similar results to 
hCMEC/D3 cells (Figure 9 and 10). Therefore, all of the similarities with primary human 
brain endothelial cells described, culturing simplicity, and extensive characterization, 
hCMEC/D3 cells are represented as an optimal model for human brain endothelial cell 
bioenergetic studies.  hCMEC/D3 cells create monolayers when in culture and appear to 
have a flat and thin structure when viewed under DIC microscopy (Figure 5).  
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Figure 5: HCMEC/D3 CELL PHOTOMICROGRAPH A photomicrograph of 
hCMEC/D3 cells at 6300X magnification and differential interference contrast (DIC). 
Cells were also exposed to MitoTracker Red and DAPI to fluorescently stain 
mitochondria (red) and nuclei (blue), respectively.   
 
Chapter 4: OCR and ECAR 
     OXPHOS generates considerably many more ATP molecules (~33) than glycolysis 
(2) per glucose molecule. ATP synthase exploits the electrical-chemical gradient of 
protons, produced from the ETC, as a driving force to convert ADP into ATP. This 
process involves the consumption of oxygen as oxygen acts as a final electron acceptor 
for the ETC and is converted into H2O. The Cell Mito Stress test was performed in order 
to measure mitochondrial characteristics and quantify respiration rates of hCMEC/D3 
cells. This assay measures oxygen consumption, in real-time, in conjunction with 
stepwise additions of oligomycin, FCCP, and Rotenone/Antimycin A in order to calculate 
various respiratory values and characteristics (Figure 6). Using this test, we were able to 
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calculate basal respiration, ATP coupled respiration, maximum respiration, spare 
respiratory capacity, proton leak, and non-mitochondrial oxygen consumption rates of 
hCMEC/D3 cells. From these oxygen consumption measurements, in real-time, 
hCMEC/D3 cells exhibited a basal mitochondrial OCR of 44.0, ATP-linked OCR of 34.9, 
proton leak OCR of 9.1, maximum respiration OCR of 70.8, and non-mitochondrial OCR 
of 27.6 pmol O2/min/10µg protein (Figure 7). hCMEC/D3 cells were also able to increase 
oxygen consumption by 26.7% and couple 79.3% of oxygen consumption to ATP 
production (Figure 7).  
 
Figure 6: HCMEC/D3 CELL OCR TRACE OCR measurements were taken in-real 
time in conjunction with step-wise injections of oligomycin, FCCP, and 
rotenone/antimycin A to characterize mitochondrial respiration values of hCMEC/D3 
cells. Real-time OCR measurements were used to calculate basal, ATP coupled, maximal 
respiration, spare respiratory capacity, proton leak, and non-mitochondrial OCR and were 
normalized to 10 µg protein. Each point represents a mean measurement of n=3 samples. 
Error bars represent the SEM. 
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Figure 7: HCMEC/D3 CELL OCR VALUES A scatter dot plot of basal, ATP coupled, 
maximal respiration spare respiratory capacity, and non-mitochondrial OCR values of 
hCMEC/D3 cells were calculated, using real-time OCR measurements with injections of 
oligomycin, FCCP, and rotenone/antimycin A (Left). The coupling efficiency and spare 
respiratory capacity percentage were also calculated for hCMEC/D3 cells (Right). All 
measurements were normalized to 10 µg protein. Each point represents one assay. Middle 
bars and error bars represent the mean and SEM of n=3 measurements, respectively. 
 
     By measuring extracellular acidification, the rate of glycolysis in hCMEC/D3 cells 
could be calculated. To measure glycolytic flux, a glycolytic rate assay was performed. 
This assay involves measuring extracellular acidification, in real-time, in conjunction 
with step-wise additions of Rotenone/Antimycin A and 2-deoxyglucose (2-DG) (Figure 
3). ECAR can be converted into PER by measuring the buffering capacity of the assay 
media. PER is considered the rate in which protons are being produced by either 
glycolysis, CO2 production, or other cellular processes. Using these measurements and 
calculations, the basal PER, glycolytic PER (glycoPER), compensatory glycolytic PER, 
and post 2-DG acidification was calculated for hCMEC/D3 cells. Cells exhibited a basal 
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PER of 498.9, glycoPER of 483.6, compensatory glycolytic PER of 566.3, and post 2-DG 
acidification of 55.0 pmol H+/min/10µg protein (Figure 8). hCMEC/D3 cells are able to 
increase glycolytic flux by 114%. Furthermore, based on basal PER and glycoPER 
values, 97.2 % of proton production is attributed to glycolysis (Figure 8). 
 
Figure 8: HCMEC/D3 PER VALUES Real-time measurements of extracellular 
acidification, in conjunction with sequential injections of rotenone/antimycin A and 2-
DG, were used to calculate glycolytic characteristics of hCMEC/D3 cells. Basal, 
glycolytic, compensatory, and post 2-DG acidification PER values (Left), along with % 
PER from glycolysis (Right), were quantified. All measurements were normalized to 10 
µg protein. Each point represents one assay. Middle bars and error bars represent the 
mean and SEM of n=3 measurements, respectively. 
 
     Given these values of mitochondrial and glycolytic characteristics, there was still the 
question of whether hCMEC/D3 cells could be used as a model for brain endothelial cell 
bioenergetic analysis. Because there are no known studies regarding brain endothelial cell 
bioenergetics via extracellular flux analysis, human primary brain microvascular 
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endothelial cell (hMVEC) bioenergetics was also analyzed. When compared to the 
measurements of hCMEC/D3 cells, hMVECs showed similar values for mitochondrial 
characteristics (Figure 9). hMVECs also exhibited similar values for glycolytic 
measurements as well (Figure 10). This further supports the use of hCMEC/D3 cells for 
bioenergetic studies of human brain microvascular endothelial cells. 
 
Figure 9: HCMEC/D3 VS. HMVEC OCR VALUES Basal, ATP coupled, proton leak, 
maximal respiration, spare respiratory capacity, and non-mitochondrial OCR values were 
measured and compared between hCMEC/D3 cells and hMVECs. All measurements 
were normalized to 10 µg protein. Each point represents the mean value of three 
experiments. Error bars represent the SEM of n=3 experiments for hCMEC/D3 cells. 
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SEM for hMVEC cells could not be measured as three experiments were taken from one 
sample. 
 
Figure 10: HCMEC/D3 VS. HMVEC PER VALUES Basal, glycolytic, compensatory, 
and post 2-DG PER values were calculated and compared between hCMEC/D3 cells and 
hMVECs. All measurements were normalized to 10 µg protein. Each point represents the 
mean value of three experiments. Error bars represent the SEM of n=3 experiments for 
hCMEC/D3 cells. SEM for hMVEC cells could not be measured as three experiments 
were taken from one sample. 
 
Chapter 5: ATP Production Rates 
     Many cellular processes require ATP to fuel metabolic and signaling pathways. Two 
main ATP producing pathways are glycolysis and OXPHOS. Brain endothelial cells use 
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ATP to perform and maintain many cellular functions, transportation, and signaling 
important for NVU integrity and function. Using equations provided by Romero et al. 
(2018), OCR and PER measurements can be used to calculate the ATP production rate 
from the mitochondria or glycolysis, respectively. Equations 1-7, below, were used to 
calculate mitochondrial and glycolytic ATP production rates for hCMEC/D3 cells. OCR 
values are in pmol O2/min, PER values are in pmol H+/min, and ATP production rates are 
in pmol/min/10 µg protein. VolXF represents the geometric volume of the sealed 
microplate well and is 2.28 µL (Equation 3). The buffer factor is calculated for each 
assay media and each assay media has a unique buffer factor. Kvol represents the volume 
scaling factor and is 1.6 for the XFe96 (Equation 3). CCF represents the CO2 
Contribution Factor, in which how much CO2 contributes to ECAR measurements, and 
has a value of 0.61 for the XFe96 (Equation 4).  Equations are provided by Romero et al. 
(2018). 
Equation 1 Glycolytic ATP production rate = GlycoPER 
Equation 2 glycoPER = PER - mitoPER 
Equation 3 PER = ECAR x Buffer Factor x VolXF microchamber x Kvol 
Equation 4 mitoPER = mitoOCR x CCF 
Equation 5 mitoOCR = OCRbasal - OCRrot/AA 
Equation 6 OCRATP = OCRbasal - OCRoligo 
Equation 7 Mitochondrial ATP production rate = OCRATP x 2 x P/O 
 
 
The difference in OCR between basal measurements and following addition of 
oligomycin, an ATP synthase inhibitor, is proportional to the amount of OCR coupled 
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with ATP production. This value is then multiplied by two, to convert to O atoms, and 
also multiplied by the number of molecules of ATP synthesized per atom of O (P/O 
value). The P/O ratio values may differ slightly based on cell types and metabolite 
composition. However, a P/O ratio value of 2.75 seemed to be the most fitting for 
multiple cell types, according to Romero et al. (2018).  Given this information, a P/O 
value of 2.75 was used for hCMEC/D3 cells [71]. Glycolytic ATP rates can be calculated 
by using glycoPER values. Glycolysis produces two ATP molecules and two lactate 
molecules, which are subsequently exported with a proton, therefore, proton production 
from glycolysis is directly proportional to glycolytic ATP production. OCR and PER 
measurements of hCMEC/D3 revealed that the ATP production rates from glycolysis and 
OXPHOS are 527.8 and 88.4 pmol ATP/min/10 µg protein, respectively (Figure 11). 
Therefore, the total ATP production rate of hCMEC/D3 cells is 616.2 pmol 
ATP/min/10µg protein (Figure 11), where 85.7% is contributed from glycolysis and 
14.3% is contributed from OXPHOS. The glycolytic ATP production rate of these cells is 
significantly higher than the mitochondrial ATP production rate. 
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Figure 11: HCMEC/D3 CELL ATP PRODUCTION RATES Mitochondrial, 
glycolytic, and total ATP production rates were calculated, using equations provided in 
Table 1, for hCMEC/D3 cells. All measurements were normalized to 10 µg protein. Each 
point represents a single measurement and error bars represent SEM of n=3 samples. 
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Chapter 6: Metabolite Effect on Bioenergetics 
     There are a variety of molecules that are able to fuel cellular metabolism, such as 
glucose, glutamine, and pyruvate (Figure 12). The most considerable of these molecules 
is glucose. Glucose acts as the main source of energy for cellular metabolism for many 
tissues, and cell types, and is the most abundant metabolite in blood serum [74]. Many 
molecules are also able to fuel the TCA cycle through a wide range of enzymatic 
reactions. Of these metabolites, glutamine and pyruvate are two metabolic substrates that 
are able to enter the TCA cycle with ease and are readily available in blood serum 
[48,74,75]. Utilizing glucose, glutamine, and pyruvate allows cells to generate molecules 
necessary for macromolecules, amino acids, nucleic acids, various cellular compartments, 
and to maintain cellular ATP production [37,44,56,57]. Based on the availability of these 
metabolites, distinct cell types may be able to utilize different metabolites to fuel ATP 
production. hCMEC/D3 cells were presented with 5 mM of glucose, glutamine, pyruvate, 
glucose + glutamine, glucose + pyruvate, glutamine + pyruvate, and all three metabolites. 
Using timed injections of oligomycin, FCCP, and rotenone/antimycin A (Figures 13 and 
14), oxygen consumption, glycolysis, and ATP production rates were measured, using 
extracellular flux analysis, based on these metabolites and combinations. An equal 
concentration (5 mM) of each metabolite was used to eliminate preference based on 
concentration.  
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Figure 12: CELLULAR METABOLITE PATHWAYS A schematic representation of 
common cellular energy producing pathways of glucose, pyruvate, and glutamine. 
LDH=lactate dehydrogenase, GLS=glutaminase, GLUD=glutamate dehydrogenase, ME= 
malic enzyme, MDH= malate dehydrogenase, and CMA/MAS= citrate malate 
antiporter/malate aspartate shuttle. 
 
     Complete Media: 
     In the presence of assay media containing all three metabolites, at 5 mM 
concentrations, the basal OCR of hCMEC/D3 cells was 57.6 pmol O2/min/10 µg protein 
(Figure 15). Mitochondrial respiration values calculated from OCR measurements, in 
real-time, displayed ATP coupled OCR of 44.7 pmol O2/min/10 µg protein, resulting in 
77.8% of basal oxygen being coupled with ATP production (Figures 16 and 17). 
Maximal respiration and spare respiratory capacity OCR values were 90.2 and 32.6 pmol 
O2/min/10 µg protein, respectively (Figures 18 and 19). Lastly, proton leak and non-
mitochondrial OCR values were calculated to be 12.8 and 21.9 pmol O2/min/10 µg 
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protein, respectively (Figures 20 and 21). From PER measurements, the compensatory 
PER was calculated as 244.6 pmol H+/min/ 10 µg protein (Figure 22). Using OCR and 
PER measurements, we were able to also calculate mitochondrial and glycolytic ATP 
production rates, respectively. Calculated mitochondrial and glycolytic ATP production 
rates were 246.1 and 199.5 pmol ATP/min/10 µg protein, respectively (Figures 23 and 
24). Therefore, the total ATP production rate was 445.6 pmol ATP/min/10 µg protein 
(Figure 25). 
     Glucose Media: 
     When 5 mM glucose was the only available metabolite, Basal OCR showed to be 
significantly lower than cells in the complete media (Figure 15). Basal OCR of 
hCMEC/D3 cells in glucose only media was calculated to be 34.2 pmol O2/min/10 µg 
protein (Figure 15). ATP coupled OCR was also lowered in glucose compared to 
complete media (Figure 16). However, the coupling efficiency was not affected (Figure 
17). Mitochondrial respiration values calculated from OCR measurements, in real-time, 
displayed ATP coupled OCR of 25.0 pmol O2/min/10 µg protein, resulting in 72.9% of 
basal oxygen being coupled with ATP production (Figures 16 and 17). Maximal 
respiration and, subsequently, spare respiratory capacity were also significantly lower 
compared to cells in complete media (Figures 18 and 19). Maximal respiration and spare 
respiratory capacity OCR values were 19.2 and -15.0 pmol O2/min/10 µg protein, 
respectively (Figures 18 and 19). Both proton leak and non-mitochondrial OCR did not 
change in cells with only glucose as a metabolite (Figures 20 and 21). Proton leak and 
non-mitochondrial OCR values were calculated to be 9.2 and 20.7 pmol O2/min/10 µg 
protein, respectively (Figures 20 and 21). From PER measurements, the compensatory 
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PER was calculated as 90.7 pmol H+/min/ 10 µg protein (Figure 22). The mitochondrial 
ATP production rate in hCMEC/D3 cells was lowered with glucose as the only available 
metabolite (Figure 23). However, the glycolytic ATP production rate increased compared 
to cell in complete media (Figure 24). Calculated mitochondrial and glycolytic ATP 
production rates were 137.4 and 323.6 pmol ATP/min/10 µg protein, respectively 
(Figures 23 and 24). However, total ATP production rates did not change compared to the 
complete media (Figure 25). The total ATP production rate in hCMEC/D3 cells in 
glucose only media, therefore, was 461.0 pmol ATP/min/10 µg protein (Figure 25). 
     Glutamine Media: 
     When in the presence of assay media containing 5 mM glutamine only, the basal OCR 
of hCMEC/D3 cells was significantly higher than cells in complete media (Figure 15). 
Basal OCR of cells in glutamine was calculated as 82.7 pmol O2/min/10 µg protein 
(Figure 15). Similarly, ATP coupled OCR in cells with glutamine only was also higher 
than cells in complete media (Figure 16). However, the coupling efficiency did not 
change (Figure 17). Mitochondrial respiration values calculated from OCR 
measurements, in real-time, displayed ATP coupled OCR of 61.5 pmol O2/min/10 µg 
protein (Figure 16), resulting in 74.3% of basal oxygen being coupled with ATP 
production (Figure 17). Calculated maximal respiration and spare respiratory capacity 
OCR values were lower than values of cells in complete media (Figures 18 and 19). 
Maximal respiration and spare respiratory capacity OCR values were 65.3 and -17.4 pmol 
O2/min/10 µg protein, respectively (Figures 18 and 19).  Cells in media with glutamine 
alone showed higher proton leak OCR than cells in complete media (Figure 20). 
However, non-mitochondrial OCR was not changed (Figure 21). Proton leak and non-
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mitochondrial OCR values were calculated to be 21.2 and 25.0 pmol O2/min/10 µg 
protein, respectively (Figures 20 and 21). From PER measurements, the compensatory 
PER was calculated as -23.1 pmol H+/min/ 10 µg protein (Figure 22). Calculated 
mitochondrial ATP production rates of cells in glutamine media were higher than cells in 
complete media (Figure 23). However, glycolytic ATP production rates were much lower 
than cells in complete media (Figure 24). Calculated mitochondrial and glycolytic ATP 
production rates were 338.4 and 9.2 pmol ATP/min/10 µg protein, respectively (Figures 
23 and 24). The total ATP production rate was 347.6 pmol ATP/min/10 µg protein, 
which showed to be lower than cells in the complete media (Figure 25). 
     Pyruvate Media: 
     In the presence of assay media containing 5 mM pyruvate, hCMEC/D3 cells displayed 
higher basal OCR values than cells in complete media (Figure 15). Basal OCR of 
hCMEC/D3 cells in pyruvate media was calculated as 76.7 pmol O2/min/10 µg protein 
(Figure 15). ATP coupled OCR values was also higher in cells with pyruvate as an only 
metabolite than cells in complete media (Figure 16). Coupling efficiency, however, was 
not altered compared to cells in complete media (Figure 17). Mitochondrial respiration 
values calculated from OCR measurements, in real-time, displayed ATP coupled OCR of 
65.0 pmol O2/min/10 µg protein (Figure 16), resulting in 84.7% of basal oxygen being 
coupled with ATP production (Figure 17). Maximal respiration OCR did not show any 
difference compared to cells in complete media (Figure 18). However, spare respiratory 
capacity OCR values was significantly lower than complete media (Figure 19). Maximal 
respiration and spare respiratory capacity OCR values were 74.3 and -2.4 pmol 
O2/min/10 µg protein, respectively (Figures 18 and 19). Proton leak and non-
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mitochondrial OCR values of cells with pyruvate alone showed to be higher than 
complete media cells (Figures 20 and 21). Calculated proton leak and non-mitochondrial 
OCR values were calculated to be 11.7 and 28.3 pmol O2/min/10 µg protein, respectively 
(Figures 20 and 21). From PER measurements, the compensatory PER was calculated as 
-37.9 pmol H+/min/ 10 µg protein (Figure 22). Mitochondrial ATP production rates were 
significantly higher in cells treated with pyruvate (Figure 23). Contrarily, glycolytic ATP 
production rates were lower for cells with pyruvate media compared to complete media 
(Figure 24). Calculated mitochondrial and glycolytic ATP production rates were 357.7 
and 26.4 pmol ATP/min/10 µg protein, respectively (Figures 23 and 24). Total ATP 
production rates, however, did not change for cells in pyruvate media in comparison to 
complete media (Figure 25). The total ATP production rate was 384.0 pmol ATP/min/10 
µg protein (Figure 25). 
     Glucose + Glutamine Media: 
     hCMEC/D3 cells, when treated with 5 mM glucose and glutamine, exhibited basal 
OCR values that were significantly lower than cells in complete media (Figure 15). The 
calculated basal OCR of hCMEC/D3 cells in glucose + glutamine media was 41.5 pmol 
O2/min/10 µg protein (Figure 15). ATP coupled OCR was also lower in cells with 
glucose and glutamine as metabolites in comparison to cells in complete media (Figure 
16). The coupling efficiency, however, was not different than complete media cells 
(Figure 17). OCR measurements, in real-time, displayed ATP coupled OCR of 30.1 pmol 
O2/min/10 µg protein (Figure 16), resulting in 72.5% of basal oxygen being coupled with 
ATP production (Figure 17). Maximal respiration and spare respiratory capacity OCR 
values in cells with glucose and glutamine were also lower than cells in complete media 
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(Figures 18 and 19). Calculated maximal respiration and spare respiratory capacity OCR 
values were 45.4 and 3.9 pmol O2/min/10 µg protein, respectively (Figures 18 and 19). 
Proton leak and non-mitochondrial oxygen consumption values of cells, in glucose and 
glutamine media, did not exhibit a significant difference when compared to cells in 
complete media (Figures 20 and 21). Proton leak and non-mitochondrial OCR values 
were calculated to be 11.4 and 20.3 pmol O2/min/10 µg protein, respectively (Figures 20 
and 21). From PER measurements, the compensatory PER was calculated as 168.5 pmol 
H+/min/ 10 µg protein (Figure 22). Mitochondrial ATP production rates in cells with 
glucose and glutamine as metabolites was lower than cells in complete media (Figure 23). 
In contrast, glycolytic ATP production rates were significantly higher compared to cells 
in complete media (Figure 24). Calculated mitochondrial and glycolytic ATP production 
rates were 165.7 and 327.3 pmol ATP/min/10 µg protein, respectively (Figures 23 and 
24). The total ATP production rates, for cells in glucose + glutamine media, remained 
unchanged from cells in complete media (Figure 25). The total ATP production rate was 
493.0 pmol ATP/min/10 µg protein (Figure 25). 
     Glucose + Pyruvate Media: 
     hCMEC/D3 cells, in the presence of assay media containing 5 mM glucose and 
pyruvate, showed lower basal OCR values than cells in complete media (Figure 15). The 
calculated basal OCR of cells in glucose + pyruvate media was 42.9 pmol O2/min/10 µg 
protein (Figure 15). Cells in glucose + pyruvate media also had decreased ATP coupled 
OCR values in comparison to cells in complete media (Figure 16). Coupling efficiency 
remained statistically unchanged compared to cells in complete media (Figure 17). 
Mitochondrial respiration values calculated from OCR measurements, in real-time, 
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displayed ATP coupled OCR of 33.4 pmol O2/min/10 µg protein (Figure 16), resulting in 
77.8% of basal oxygen being coupled with ATP production (Figure 17). Cells treated 
with glucose and pyruvate displayed maximal respiration and spare respiratory capacity 
OCR values lower than cells in complete media (Figures 18 and 19). Calculated maximal 
respiration and spare respiratory capacity OCR values were 41.0 and -2.0 pmol 
O2/min/10 µg protein, respectively (Figures 18 and 19). Cells in glucose + pyruvate did 
not exhibit changes in either proton leak or non-mitochondrial oxygen consumption when 
compared to cells in complete media (Figures 20 and 21). Proton leak and non-
mitochondrial OCR values were calculated to be 9.5 and 20.5 pmol O2/min/10 µg 
protein, respectively (Figures 20 and 21). From PER measurements, the compensatory 
PER was calculated as 117.1 pmol H+/min/ 10 µg protein (Figure 22). Mitochondrial 
ATP production rates of cells in glucose + pyruvate media decreased in comparison to 
cells in complete media, while glycolytic ATP production rates increased (Figures 23 and 
24). Calculated mitochondrial and glycolytic ATP production rates were 183.7 and 235.5 
pmol ATP/min/10 µg protein, respectively (Figures 23 and 24). Total ATP production 
rates did not change between the two media groups (Figure 25). Total ATP production 
rate was 419.2 pmol ATP/min/10 µg protein (Figure 25). 
     Glutamine + Pyruvate Media: 
     Lastly, cells in the presence of assay media containing 5 mM glutamine and pyruvate 
displayed higher basal OCR values compared to cells in complete media (Figure 15). The 
basal OCR of hCMEC/D3 cells was calculated as 86.9 pmol O2/min/10 µg protein 
(Figure 15). Similarly, ATP coupled OCR values were significantly higher than those of 
complete media (Figure 16). Coupling efficiency was not different bet
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media groups, though (Figure 17). OCR measurments, in real-time, revealed ATP 
coupled OCR of 67.8 pmol O2/min/10 µg protein (Figure 16), resulting in 78.0% of basal 
oxygen being coupled with ATP production (Figure 17). Cells in glutamine + pyruvate 
media showed lower maximal respiration and spare respiratory values than cells in 
complete media (Figures 18 and 19). Maximal respiration and spare respiratory capacity 
OCR values were calculated to be 66.5 and -20.4 pmol O2/min/10 µg protein, 
respectively (Figures 18 and 19). Cells in glutamine + pyruvate media exhibited higher 
proton leak and non-mitochondrial OCR values than complete media cells (Figures 20 
and 21). Proton leak and non-mitochondrial OCR values were calculated to be 19.1 and 
29.1 pmol O2/min/10 µg protein, respectively (Figures 20 and 21). From PER 
measurements, the compensatory PER was calculated as -33.6 pmol H+/min/ 10 µg 
protein (Figure 22). Calculated mitochondrial and glycolytic ATP production rates were 
higher and lower, respectively, compared to complete media (Figures 23 and 24). 
Mitochondrial and glycolytic ATP production rates were 372.8 and 29.9 pmol 
ATP/min/10 µg protein, respectively (Figures 23 and 24). The total ATP production rate 
was 402.7 pmol ATP/min/10 µg protein, which was not significantly different than cells 
in complete media (Figure 25). 
     Interestingly, though mitoATP and glycoATP production rates of hCMEC/D3 cells 
increased or decreased based on media composition, the total ATP production rate was 
able to be maintained for all, besides glutamine, metabolite groups. hCMEC/D3 cells in 
all media groups also showed lower total ATP production rates than cells in assay media 
containing glucose, glutamine, and pyruvate at concentrations of 5.83 mM, 1.5 mM, and 
1 mM, respectively. 
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Figure 13: HCMEC/D3 CELL METABOLITE OCR TRACE (A) OCR and ECAR 
(not shown) measurements were taken in-real time and in conjunction with step-wise 
injections of oligomycin, FCCP, and rotenone/antimycin A to characterize mitochondrial 
respiration, glycolytic, and ATP production rate values of hCMEC/D3 cells. Real-time 
measurements shown are from cells treated with a complete media consisting of 5 mM 
glucose + 5 mM glutamine + 5 mM pyruvate, 5 mM glucose, 5 mM glucose + 5 mM 
pyruvate, or 5 mM glucose + 5 mM glutamine. Measurements were normalized to 10 µg 
protein. Each point represents a mean measurement and error bars represent SEM of n=3 
samples. 
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Figure 14: HCMEC/D3 CELL METABOLITE OCR TRACE (B) OCR and ECAR 
(not shown) measurements were taken in-real time and in conjunction with step-wise 
injections of oligomycin, FCCP, and rotenone/antimycin A to characterize mitochondrial 
respiration, glycolytic, and ATP production rate values of hCMEC/D3 cells. Real-time 
measurements shown are from cells treated with a complete media consisting of 5 mM 
glucose + 5 mM glutamine + 5 mM pyruvate, 5 mM glutamine, 5 mM pyruvate, or 5 mM 
glutamine + 5 mM pyruvate. Measurements were normalized to 10 µg protein. Each point 
represents a mean measurement and error bars represent SEM of n=3 samples. 
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Table 1: HCMEC/D3 CELL METABOLITE ENERGETIC VALUES OCR, 
Compensatory PER (Comp PER), mitochondrial ATP production rate (mitoATP), 
glycolytic ATP production rate (glycoATP), and total ATP production rate values were 
calculated for cells treated with each media type. OCR, PER, and ATP production rate 
values are expressed as pmol O2, H+, and ATP/min/10 µg protein, respectively 
  
Basal 
OCR 
ATP 
coupled 
OCR 
Coupling 
Efficiency 
(%) 
Maximal 
Respiration 
OCR 
Spare 
Respiratory 
Capacity 
OCR 
Proton 
Leak 
OCR 
Complete 
Media 57.6 44.7 77.8 90.2 32.6 12.8 
Glucose 
Media 34.2 25.0 72.9 19.2 -15.0 9.2 
Glucose + 
Glutamine 
Media 41.5 30.1 72.5 45.4 3.9 11.4 
Glucose + 
Pyruvate 
Media 42.9 33.4 77.8 41.0 -2.0 9.5 
Pyruvate 
Media 76.7 65.0 84.7 74.3 -2.4 11.7 
Glutamine 
Media 82.7 61.5 74.3 65.3 -17.4 21.2 
Glutamine 
+ Pyruvate 
Media 86.9 67.8 78.0 66.5 -20.4 19.1 
  
Non-mito 
OCR 
Comp 
PER mitoATP glycoATP Total ATP 
Complete 
Media 21.9 244.6 246.1 199.5 445.6 
Glucose 
Media 20.7 90.7 137.4 323.6 461.0 
Glucose + 
Glutamine 
Media 20.3 168.5 165.7 327.3 493.0 
Glucose + 
Pyruvate 
Media 20.5 117.1 183.7 235.5 419.2 
Pyruvate 
Media 28.3 -37.9 357.7 26.4 384.0 
Glutamine 
Media 25.0 -23.1 338.4 9.2 347.6 
Glutamine 
+ Pyruvate 
Media 29.1 -33.6 372.8 29.9 402.7 
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Figure 15: HCMEC/D3 METABOLITE BASAL OCR Basal OCR values of 
hCMEC/D3 cells were calculated, based on real-time OCR measurements, for each 
metabolite group. Values from each metabolite group were compared to each other 
group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 16: HCMEC/D3 METABOLITE ATP COUPLED OCR ATP coupled OCR 
values of hCMEC/D3 cells were calculated, based on real-time OCR measurements, for 
each metabolite group. Values from each metabolite group were compared to each other 
group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 17: HCMEC/D3 METABOLITE COUPLING EFFICIENCY Coupling 
efficiency of hCMEC/D3 cells were calculated, based on real-time OCR measurements, 
for each metabolite group. Values from each metabolite group were compared to each 
other group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 18: HCMEC/D3 METABOLITE MAXIMAL RESPIRATION Maximal 
respiration OCR values of hCMEC/D3 cells were calculated, based on real-time OCR 
measurements, for each metabolite group. Values from each metabolite group were 
compared to each other group. All measurements were normalized to 10 µg protein. Each 
point represents a single measurement and error bars represent SEM of n=3 samples. 
Shared letters indicate no significant difference. Absence of a shared letter indicates a 
significant difference between groups. 
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Figure 19: HCMEC/D3 METABOLITE SPARE RESPIRATORY CAPACITY 
Spare respiratory capacity OCR values of hCMEC/D3 cells were calculated, based on 
real-time OCR measurements, for each metabolite group. Values from each metabolite 
group were compared to each other group. All measurements were normalized to 10 µg 
protein. Each point represents a single measurement and error bars represent SEM of n=3 
samples. Shared letters indicate no significant difference. Absence of a shared letter 
indicates a significant difference between groups. 
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Figure 20: HCMEC/D3 METABOLITE PROTON LEAK Proton leak OCR values of 
hCMEC/D3 cells were calculated, based on real-time OCR measurements, for each 
metabolite group. Values from each metabolite group were compared to each other 
group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 21: HCMEC/D3 METABOLITE NON-MITOCHONDRIAL OCR Non-
mitochondrial OCR values of hCMEC/D3 cells were calculated, based on real-time OCR 
measurements, for each metabolite group. Values from each metabolite group were 
compared to each other group. All measurements were normalized to 10 µg protein. Each 
point represents a single measurement and error bars represent SEM of n=3 samples. 
Shared letters indicate no significant difference. Absence of a shared letter indicates a 
significant difference between groups. 
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Figure 22: HCMEC/D3 METABOLITE COMPENSATORY PER Compensatory 
PER values of hCMEC/D3 cells were calculated, based on real-time PER measurements, 
for each metabolite group. Values from each metabolite group were compared to each 
other group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 23: HCMEC/D3 METABOLITE MITOCHONDRIAL ATP PRODUCTION 
RATES Mitochondrial ATP production rates values of hCMEC/D3 cells were calculated, 
based on real-time OCR measurements, for each metabolite group. Values from each 
metabolite group were compared to each other group. All measurements were normalized 
to 10 µg protein. Each point represents a single measurement and error bars represent 
SEM of n=3 samples. Shared letters indicate no significant difference. Absence of a 
shared letter indicates a significant difference between groups. 
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Figure 24: HCMEC/D3 METABOLITE GLYCOLYTIC ATP PRODUCTION 
RATES Glycolytic ATP production rates values of hCMEC/D3 cells were calculated, 
based on real-time PER measurements, for each metabolite group. Values from each 
metabolite group were compared to each other group. All measurements were normalized 
to 10 µg protein. Each point represents a single measurement and error bars represent 
SEM of n=3 samples. Shared letters indicate no significant difference. Absence of a 
shared letter indicates a significant difference between groups. 
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Figure 25: HCMEC/D3 METABOLITE TOTAL ATP PRODUCTION RATES 
Total ATP production rates values of hCMEC/D3 cells were calculated, by adding 
mitochondrial and glycolytic ATP production rates, for each metabolite group. Values 
from each metabolite group were compared to each other group. All measurements were 
normalized to 10 µg protein. Each point represents a single measurement and error bars 
represent SEM of n=3 samples. Shared letters indicate no significant difference. Absence 
of a shared letter indicates a significant difference between groups. 
 
Chapter 7: Inhibitor Effect on Bioenergetics 
     Transport proteins are essential in cellular metabolism. In order to utilize various 
molecules for cellular metabolism, the cells should be able to transport those metabolites, 
via transmembrane proteins, into the cytoplasm from the extracellular space or from the 
cytoplasm to the mitochondrial matrix (Figure 26). Depending on expression levels, 
kinetics, and location, both passive and active transport mechanisms can dictate the rate 
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of which metabolites may enter, or exit, the cellular compartment. Transport mechanisms 
may also dictate the rate of TCA cycle reactions and OXPHOS, as well as glycolytic 
rates. These metabolic pathways, in turn, may dictate the rate in which ATP is produced 
within the cell. Important metabolite transporters include GLUT1, a primary glucose 
transporter, and those of the solute carrier family. Solute carrier proteins for pyruvate, 
lactate, and glutamine include SLC16A1 (MCT1), SLC16A3 (MCT4), and SLC1A5 
(ACST2) [8,53,76]. Pyruvate and lactate, both monocarboxylates, import or export is 
governed by MCTs 1 and 4, which act as symporters with H+ ions [8,41]. ACST2 is 
mainly responsible for glutamine transport and acts as an antiporter with Na+ ions 
[53,76]. Pyruvate is transported into the mitochondria, to fuel the TCA cycle, by MPC 
[58,77,78]. Glutamine is converted to glutamate, via glutaminase (GLS), which then 
enters the TCA cycle by being converted into alpha-ketoglutarate [44,45]. 
     Inhibiting GLUT1, MCT1, MPC, and GLS revealed insights for hCMEC/D3 
metabolic plasticity and ability to compensate for metabolic pathway disruption. In order 
to inhibit GLUT1, MCT1, MPC, and GLS, small molecule inhibitors were used. These 
inhibitors are named BAY876, AZD3965, UK5099, and BPTES, respectively (Figure 
25). An experimental small molecule inhibitor, named MD1, was also tested. MD1 is an 
experimental duo MCT1/MCT4 inhibitor developed by the lab of Dr. Venkatram 
Mereddy at the University of Minnesota, Duluth Campus. Concentrations used for 
inhibitors were determined based on experiments performed by other investigators in 
literature and extracellular flux analysis assays. Concentrations that exhibited a robust 
response in PER or OCR were used for final ATP rate assays. Extracellular flux analysis 
was performed, using individual inhibitors and combinations, to determine OCR, PER, 
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and ATP production rate plasticity in hCMEC/D3 cells. Inhibitor combinations used were 
BAY876 + UK5099, BAY876 + BPTES, BAY876 + MD1, and BAY876 + UK5099 + 
BPTES. 
 
Figure 26: INHIBITOR TARGETS A schematic representation of common cellular 
energy producing pathways of glucose, pyruvate, and glutamine. Inhibitors tested include 
BAY876, AZD3965, MD1, UK5099, and BPTES. These inhibit glucose transporter 1 
(GLUT1), monocarboxylate transporter 1 (MCT1), mitochondrial pyruvate carrier 
(MPC), and glutaminase (GLS), respectively. LDH=lactate dehydrogenase, 
GLUD=glutamate dehydrogenase, ME= malic enzyme, MDH= malate dehydrogenase, 
and CMA/MAS= citrate malate antiporter/malate aspartate shuttle. 
 
     Control: 
     Unlike complete media, control media consisted of 5.83 mM glucose, 1.5 mM 
glutamine, and 1 mM pyruvate. With no inhibitors present, hCMEC/D3 cells exhibited a 
basal OCR value of 25.6 and an ATP coupled OCR value of 16.1 pmol O2/min/10 µg 
protein (Figures 29 and 30). Given these measurements, the coupling efficiency was 
calculated and showed that hCMEC/D3 cells were able to couple 62.9% of the OCR with 
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ATP production (Figure 31). Maximal respiration and spare respiratory capacity OCR 
values were 39.8 and 14.2 pmol O2/min/10 µg protein, respectively (Figure 32 and 33). 
Proton leak and non-mitochondrial OCR measurements for hCMEC/D3 cells were also 
calculated as 9.5 and 20.6 pmol O2/min/10 µg protein, respectively (Figures 34 and 35). 
PER measurements indicated a compensatory PER of 38.2 pmol H+/min/10 µg protein 
(Figure 36). Using OCR and PER measurements, mitochondrial and glycolytic ATP 
production rates were also calculated for hCMEC/D3 cells. The mitochondrial and 
glycolytic ATP production rates were 88.4 and 527.8 pmol ATP/min/10 µg protein, 
respectively (Figures 37 and 38). Therefore, the total ATP production rate of hCMEC/D3 
cells was 616.2 pmol ATP/min/10 µg protein (Figure 39).  
     BAY876 Treated Cells: 
     Inhibition of GLUT1 in hCMEC/D3 cells, by the small molecule inhibitor BAY876, 
increased both basal and ATP coupled OCR values compared to the control (Figures 29 
and 30). Calculated basal and ATP coupled OCR values for BAY876 treated cells were 
55.7 and 41.7 pmol O2/min/10 µg protein, respectively (Figures 29 and 30). Given these 
values, 74.9% of the basal OCR is able to be coupled with ATP production (Figure 31). 
This coupling efficiency is also significantly higher than control cells (Figure 31). Cells 
treated with BAY876 also exhibited an increase in maximal respiration and spare 
respiratory capacity (Figures 32 and 33). Calculated maximal respiration and spare 
respiratory capacity values were 78.6 and 22.9 pmol O2/min/10 µg protein, respectively 
(Figures 32 and 33). The proton leak OCR values of cells treated with BAY876 showed 
to be higher than control cells (Figure 34). The calculated proton leak OCR was 13.9 
pmol O2/min/10 µg protein (Figure 34). Non-mitochondrial OCR, calculated to be 23.2 
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pmol O2/min/10 µg protein, was not significantly different than the control (Figure 35). 
PER measurements indicated a compensatory PER of -3.6 pmol H+/min/10 µg protein 
(Figure 36). Treatment with BAY876 increased the mitochondrial ATP production rate in 
hCMEC/D3 cells, but in contrast, decreased the glycolytic ATP production rate 
significantly (Figures 37 and 38). Mitochondrial and glycolytic ATP production rates 
were calculated as 229.6 and 103.9 pmol ATP/min/10µg protein, respectively (Figures 37 
and 38). BAY876 showed to significantly decrease the total ATP production rate in 
hCMEC/D3 cells (Figure 39). The total ATP production rate was calculated as 333.5 
pmol/min/10 µg protein (Figure 39). 
     AZD3965 Treated Cells: 
     MCT1 inhibition by AZD3965 exhibited no change in basal OCR or ATP coupled 
OCR in hCMEC/D3 cells (Figures 29 and 30). Calculated basal and ATP coupled OCR 
values for AZD3965 treated cells were 30.4 and 19.5 pmol O2/min/10 µg protein, 
respectively (Figures 29 and 30). The coupling efficiency of cells treated with AZD3965 
did not change as well (Figure 31). It was calculated that 64.1% of the basal OCR was 
able to be coupled with ATP production (Figure 31). Cells treated with AZD3965 also 
did not exhibit any significant change in maximal respiration and spare respiratory 
capacity compared to control cells (Figures 32 and 33). Calculated maximal respiration 
and spare respiratory capacity values were 48.8 and 18.4 pmol O2/min/10 µg protein, 
respectively (Figures 32 and 33). There was also no change in proton leak and non-
mitochondrial OCR values, of cells treated with AZD3965, compared to the control 
(Figures 34 and 35). The calculated proton leak and non-mitochondrial OCR was 10.9 
and 22.5 pmol O2/min/10 µg protein (Figures 34 and 35). PER measurements indicated a 
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compensatory PER of 47.5 pmol H+/min/10 µg protein (Figure 36). Treatment with 
AZD3965 did not significantly alter the mitochondrial or glycolytic ATP production rate 
in hCMEC/D3 cells (Figures 37 and 38). Mitochondrial and glycolytic ATP production 
rates were calculated as 107.0 and 438.8 pmol ATP/min/10µg protein, respectively 
(Figures 37 and 38). AZD3965 treatment also did not alter the total ATP production rate 
in hCMEC/D3 cells (Figure 39). The total ATP production rate was calculated as 545.9 
pmol/min/10 µg protein (Figure 39). 
     MD1 Treated Cells: 
     Using the experimental small molecule inhibitor, MD1, treated cells did not show a 
significant difference in either basal or ATP coupled OCR values, compared to control 
cells (Figures 29 and 30). Calculated basal and ATP coupled OCR values for cells treated 
with MD1 were 29.2 and 13.3 pmol O2/min/10 µg protein, respectively (Figures 29 and 
30). Coupling efficiency of cells treated with MD1 was significantly lower than control 
cells as 45.5% of basal OCR was calculated to be for ATP production (Figure 31). 
Maximal respiration and spare respiratory capacity OCR values of treated cells were 
significantly lower than control cells (Figures 32 and 33). Calculated maximal respiration 
and spare respiratory capacity values were 17.5 and -11.7 pmol O2/min/10 µg protein, 
respectively (Figures 32 and 33). Proton leak of cells treated with MD1 was shown to be 
significantly higher than the control (Figure 34). Non-mitochondrial OCR values 
remained unchanged compared to the control (Figure 35). The calculated proton leak and 
non-mitochondrial OCR values were 15.9 and 22.9 pmol O2/min/10 µg protein, 
respectively (Figures 34 and 35). PER measurements indicated a compensatory PER of 
17.1 pmol H+/min/10 µg protein (Figure 36). Mitochondrial and glycolytic ATP 
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production rate in hCMEC/D3 cells treated with MD1 did not show a significant 
difference than the control cells (Figures 37 and 38). Mitochondrial and glycolytic ATP 
production rates were calculated as 73.4 and 574.3 pmol ATP/min/10µg protein, 
respectively (Figures 37 and 38). The total ATP production rate in hCMEC/D3 cells 
treated with MD1 was, therefore, not different than control cells (Figure 39). The total 
ATP production rate was calculated as 647.7 pmol/min/10 µg protein (Figure 39). 
     UK5099 Treated Cells: 
     Inhibiting MPC, via UK5099, in hCMEC/D3 cells did not significantly alter either 
basal and ATP coupled OCR values compared to the control (Figures 29 and 30). 
Calculated basal and ATP coupled OCR values for cells exposed to UK5099 were 23.8 
and 14.1 pmol O2/min/10 µg protein, respectively (Figures 29 and 30). Coupling effiency 
of cells treated with UK5099 did not change compared to the control (Figure 31). Basal 
OCR coupled with ATP production was calculated as 58.2% (Figure 31). Cells treated 
with UK5099 displayed a decrease in maximal respiration and spare respiratory capacity. 
Calculated maximal respiration and spare respiratory capacity values were 16.9 and -6.5 
pmol O2/min/10 µg protein, respectively. There was no significant difference in proton 
leak and non-mitochondrial OCR values of cells treated with UK5099 compared to 
control cells. The calculated proton leak and non-mitochondrial OCR values were 9.8 and 
18.3 pmol O2/min/10 µg protein, respectively. PER measurements indicated a 
compensatory PER of 17.3 pmol H+/min/10 µg protein. Inhibition of MPC by UK5099 
did not display a significant change in mitochondrial and glycolytic ATP production rate 
in hCMEC/D3 cells. Mitochondrial and glycolytic ATP production rates were calculated 
as 77.3 and 507.1 pmol ATP/min/10µg protein, respectively. MPC inhibition did not alter 
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total ATP production rate in hCMEC/D3 cells. The total ATP production rate was 
calculated as 584.4 pmol/min/10 µg protein. 
     BPTES Treated Cells: 
     hCMEC/D3 cells treated with BPTES, a glutaminase inhibitor, did not show a 
significant change in both basal and ATP coupled OCR values compared to the control 
(Figures 29 and 30). Calculated basal and ATP coupled OCR values for BPTES treated 
cells were 14.2 and 8.3 pmol O2/min/10 µg protein, respectively (Figures 29 and 30). The 
coupling efficiency of BPTES treated cells was not significantly altered compared to 
control cells (Figure 31). The coupling efficiency of BPTES treated cells was calculated 
as 58.5% (Figure 31). Maximal respiration and spare respiratory capacity OCR values 
were significantly lower in BPTES treated cells compared to control cells (Figures 32 and 
33). Calculated maximal respiration and spare respiratory capacity values were 13.0 and -
1.2 pmol O2/min/10 µg protein, respectively (Figures 32 and 33). Proton leak and non-
mitochondrial OCR values of cells treated with BPTES exhibited no significant change 
compared to control cells (Figures 34 and 35). The calculated proton leak and non-
mitochondrial OCR values were 5.9 and 15.3 pmol O2/min/10 µg protein (Figures 34 and 
35). PER measurements indicated a compensatory PER of -32.5 pmol H+/min/10 µg 
protein (Figure 36). Mitochondrial and glycolytic ATP production rates were not 
significantly different, than control cells, in cells treated with BPTES (Figures 37 and 
38). Mitochondrial and glycolytic ATP production rates were calculated as 45.9 and 
490.3 pmol ATP/min/10µg protein, respectively (Figures 37 and 38). The total ATP 
production rate in hCMEC/D3 cells was also not significantly different in BPTES treated 
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cells (Figure 39). The total ATP production rate was calculated as 536.2 pmol/min/10 µg 
protein (Figure 39). 
     BAY876 + UK5099 Treated Cells: 
     Inhibition of GLUT1 and MPC in hCMEC/D3 cells, by the small molecule inhibitors 
BAY876 and UK5099, increased both basal and ATP coupled OCR values compared to 
the control (Figures 29 and 30). Calculated basal and ATP coupled OCR values for 
BAY876 treated cells were 50.7 and 38.2 pmol O2/min/10 µg protein, respectively 
(Figures 29 and 30). The calculated coupling efficiency is also significantly higher than 
control cells (Figure 31). hCMEC/D3 cells are able to couple 75.3% of their basal OCR 
to ATP production (Figure 31). Maximal respiration OCR was also increased in cells 
treated with BAY876 and UK5099 (Figure 32). However, spare respiratory capacity did 
not significantly change (Figure 33). Calculated maximal respiration and spare 
respiratory capacity values were 71.8 and 21.1 pmol O2/min/10 µg protein, respectively 
(Figures 32 and 33). Both proton leak and non-mitochondrial OCR values of cells treated 
with BAY876 and UK5099 were not significantly different than control cells (Figures 34 
and 35). The calculated proton leak and non-mitochondrial OCR was 12.4 and 24.1 pmol 
O2/min/10 µg protein, respectively (Figures 34 and 35). PER measurements indicated a 
compensatory PER of 10.9 pmol H+/min/10 µg protein (Figure 36). Treatment with 
BAY876 and UK5099 significantly increased the mitochondrial ATP production rate in 
hCMEC/D3 cells (Figures 37). However, the glycolytic ATP production rate significantly 
decreased as well (Figure 38). Mitochondrial and glycolytic ATP production rates were 
calculated as 210.2 and 134.1 pmol ATP/min/10µg protein, respectively (Figures 37 and 
38). BAY876 combined with UK5099 showed to significantly decrease the total ATP 
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production rate in hCMEC/D3 cells, compared to control cells (Figure 39). The total ATP 
production rate was calculated as 344.4 pmol/min/10 µg protein (Figure 39). 
     BAY876 + BPTES Treated Cells: 
     Inhibiting GLUT1 and GLS, via BAY876 and BPTES combined, increased both basal 
and ATP coupled OCR values compared to the control (Figures 29 and 30). Calculated 
basal and ATP coupled OCR values for BAY876 + BPTES treated cells were 40.3 and 
31.2 pmol O2/min/10 µg protein, respectively (Figures 29 and 30). Coupling efficiency of 
cells treated with BAY876 and BPTES was also significantly higher than control cells 
(Figure 31). The coupling efficiency revealed that cells were able to utilize 77.4% of the 
basal OCR for ATP production (Figure 31). Maximal respiration and spare respiratory 
capacity, in cells treated with BAY876 + BPTES, did not show a significant difference 
compared to control cells (Figures 32 and 33). Maximal respiration and spare respiratory 
capacity values were calculated as 59.4 and 19.1 pmol O2/min/10 µg protein, respectively 
(Figures 32 and 33). Proton leak and non-mitochondrial OCR values were not 
significantly different, in BAY876 + BPTES treated cells, than control cells (Figures 34 
and 35). Proton leak and non-mitochondrial OCR values were calculated as 9.0 and 21.4 
pmol O2/min/10 µg protein, respectively (Figures 34 and 35). PER measurements 
indicated a compensatory PER of -10.4 pmol H+/min/10 µg protein (Figure 36). 
Mitochondrial ATP production rate, in hCMEC/D3 cells treated with BAY876 + BPTES, 
was significantly higher than control cells (Figure 37). Subsequently, the glycolytic ATP 
production rate was significantly lower than control cells (Figure 38). Mitochondrial and 
glycolytic ATP production rates were calculated as 171.8 and 131.2 pmol ATP/min/10µg 
protein, respectively (Figures 37 and 38). The total ATP production rate, of cells treated 
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with BAY876 + BPTES, was significantly lower than control cells (Figure 39). The total 
ATP production rate was calculated as 302.9 pmol/min/10 µg protein (Figure 39). 
     BAY876 + MD1 Treated Cells: 
     Using BAY876 and MD1, inhibition of GLUT1 and MCT1/MCT4 in hCMEC/D3 
cells exhibited a significant increase in both basal and ATP coupled OCR values 
compared to the control (Figures 29 and 30). Calculated basal and ATP coupled OCR 
values for BAY876 + MD1 treated cells were 49.6 and 31.4 pmol O2/min/10 µg protein, 
respectively (Figures 29 and 30). The coupling efficiency, however, was not significantly 
altered (Figure 31). BAY876 + MD1 treated cells were able to couple 63.3% of their 
basal OCR to ATP production (Figure 31). Maximal respiration OCR values were higher 
in BAY876 + MD1 treated cells than control cells (Figure 32). However, the spare 
respiratory capacity remained unchanged, statistically (Figure 33). Calculated maximal 
respiration and spare respiratory capacity values were 62.3 and 12.6 pmol O2/min/10 µg 
protein, respectively (Figures 32 and 33). Proton leak OCR values, of cells treated with 
BAY876 + MD1, were significantly higher than control cells (Figure 34). The non-
mitochondrial OCR was not altered in treated cells compared to control cells (Figure 35). 
Proton leak and non-mitochondrial OCR values were calculated as 18.2 and 24.0 pmol 
O2/min/10 µg protein, respectively (Figures 34 and 35). PER measurements indicated a 
compensatory PER of 37.1 pmol H+/min/10 µg protein (Figure 36). Treatment with 
BAY876 + MD1 significantly increased the mitochondrial ATP production rate in 
hCMEC/D3 cells, however, decreased the glycolytic ATP production rate significantly 
(Figures 37 and 38). Mitochondrial and glycolytic ATP production rates were calculated 
as 172.8 and 149.1 pmol ATP/min/10µg protein, respectively (Figures 37 and 38). 
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BAY876 + MD1 showed to significantly decrease the total ATP production rate in 
hCMEC/D3 cells (Figure 39). The total ATP production rate was calculated as 321.9 
pmol/min/10 µg protein (Figure 39). 
     BAY876 + UK5099 + BPTES Treated Cells: 
     Basal and ATP coupled OCR values in cells treated with BAY876, UK5099, and 
BPTES were significantly higher than control cells (Figures 29 and 30). Calculated basal 
and ATP coupled OCR values for BAY876 + UK5099 + BPTES treated cells were 38.5 
and 28.1 pmol O2/min/10 µg protein, respectively (Figures 29 and 30). The coupling 
efficiency of cells treated with BAY876 + UK5099 + BPTES was significantly higher 
than control cells (Figure 31). The coupling efficiency was calculated as 73.0% of basal 
OCR being coupled to ATP production (Figure 31). The maximal respiration OCR for 
cells treated with BAY876 + UK5099 + BPTES was not different than control cells 
(Figure 32). However, the spare respiratory capacity was significantly lower than control 
cells (Figure 33). Calculated maximal respiration and spare respiratory capacity values 
were 40.6 and 2.1 pmol O2/min/10 µg protein, respectively (Figures 32 and 33). Proton 
leak and non-mitochondrial OCR values of cells treated with BAY876 + UK5099 + 
BPTES were not significantly altered compared to control cells (Figures 34 and 35). The 
calculated proton leak and non-mitochondrial OCR values were 10.4 and 18.9 pmol 
O2/min/10 µg protein (Figures 34 and 35). PER measurements indicated a compensatory 
PER of -5.0 pmol H+/min/10 µg protein (Figure 36). Mitochondrial ATP production rates 
in cells treated with BAY876 + UK5099 + BPTES were lower than control cells (Figure 
37). The glycolytic ATP production rate of treated cells, in contrast, was lower than 
control cells (Figure 38). Mitochondrial and glycolytic ATP production rates were 
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calculated as 154.6 and 134.8 pmol ATP/min/10µg protein, respectively (Figures 37 and 
38). The total ATP production rate in BAY876 + UK5099 + BPTES treated hCMEC/D3 
cells was lower than control cells (Figure 39). The total ATP production rate was 
calculated as 289.4 pmol/min/10 µg protein (Figure 39). 
 
 
Figure 27: HCMEC/D3 CELL INHIBITOR OCR TRACE (A) OCR and ECAR (not 
shown) measurements were taken in-real time and in conjunction with step-wise 
injections of oligomycin, FCCP, and rotenone/antimycin A to characterize mitochondrial 
respiration, glycolytic, and ATP production rate values of hCMEC/D3 cells. Real-time 
measurements shown are from cells treated with no inhibitors (control), AZD3965, 
BAY876, MD1 + BAY876, UK5099 + BAY876, and BPTES + BAY876. Measurements 
were normalized to 10 µg protein. Each point represents a mean measurement and error 
bars represent SEM of n=3 samples. 
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Figure 28: HCMEC/D3 INHIBITOR OCR TRACE (B) OCR and ECAR (not shown) 
measurements were taken in-real time and in conjunction with step-wise injections of 
oligomycin, FCCP, and rotenone/antimycin A to characterize mitochondrial respiration, 
glycolytic, and ATP production rate values of hCMEC/D3 cells. Real-time measurements 
shown are from cells treated with no inhibitors (control), MD1, UK5099, BPTES, and 
BPTES + BAY876 + UK5099. Measurements were normalized to 10 µg protein. Each 
point represents a mean measurement and error bars represent SEM of n=3 samples. 
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Table 2:  HCMEC/D3 INHIBITOR ENERGETIC VALUES OCR, compensatory 
PER (Comp PER), mitochondrial ATP production rate (mitoATP), glycolytic ATP 
production rate (glycoATP), and total ATP production rate values were calculated for 
cells treated with each inhibitor or combination. OCR, PER, and ATP production rate 
values are expressed as pmol O2, H+, and ATP/min/10 µg protein, respectively 
  
Basal 
OCR 
ATP 
coupled 
OCR 
Coupling 
efficiency 
(%) 
Maximal  
Respiration 
OCR 
Spare 
Respiratory 
Capacity OCR 
Proton 
Leak 
OCR 
Control 25.6 16.1 62.9 39.8 14.2 9.5 
BAY876 55.7 41.7 74.9 78.6 22.9 13.9 
UK5099 + 
BAY876 50.7 38.2 75.3 71.8 21.1 12.4 
MD1 + 
BAY876 49.6 31.4 63.3 62.3 12.7 18.2 
BPTES + 
BAY876 40.3 31.2 77.4 59.4 19.1 9.0 
BPTES + 
UK5099 + 
BAY876 38.5 28.1 73.0 40.6 2.1 10.4 
AZD3965 30.4 19.5 64.1 48.8 18.4 10.9 
MD1 29.2 13.3 45.5 17.5 -11.7 15.9 
UK5099 23.8 14.1 59.2 16.9 -6.9 9.8 
BPTES 14.2 8.3 58.5 13.0 -1.2 5.9 
  
Non-
mito 
OCR 
Comp 
PER mitoATP glycoATP Total ATP 
Control 20.6 38.2 88.4 527.8 616.2 
BAY876 23.2 -3.6 229.6 103.9 333.5 
UK5099 + 
BAY876 24.1 10.9 210.2 134.1 344.4 
MD1 + 
BAY876 24.0 37.1 172.8 149.1 321.9 
BPTES + 
BAY876 21.4 -10.4 171.8 131.2 302.9 
BPTES + 
UK5099 + 
BAY876 18.9 -5.0 154.6 134.8 289.4 
AZD3965 22.5 47.5 107.0 438.8 545.9 
MD1 22.9 17.1 73.4 574.3 647.7 
UK5099 18.3 17.3 77.3 507.1 584.4 
BPTES 15.3 -32.5 45.9 490.3 536.2 
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Figure 29: HCMEC/D3 INHIBITOR BASAL OCR Basal OCR values of hCMEC/D3 
cells were calculated, based on real-time OCR measurements, for each inhibitor treatment 
group. Values from each inhibitor group were compared to each other group. All 
measurements were normalized to 10 µg protein. Each point represents a single 
measurement and error bars represent SEM of n=3 samples. Shared letters indicate no 
significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 30: HCMEC/D3 INHIBITOR ATP COUPLED OCR ATP coupled OCR 
values of hCMEC/D3 cells were calculated, based on real-time OCR measurements, for 
each inhibitor treatment group. Values from each inhibitor group were compared to each 
other group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 31: HCMEC/D3 INHIBITOR COUPLING EFFICIENCY Coupling 
efficiencies of hCMEC/D3 cells were calculated, based on real-time OCR measurements, 
for each inhibitor treatment group. Values from each inhibitor group were compared to 
each other group. All measurements were normalized to 10 µg protein. Each point 
represents a single measurement and error bars represent SEM of n=3 samples. Shared 
letters indicate no significant difference. Absence of a shared letter indicates a significant 
difference between groups. 
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Figure 32: HCMEC/D3 INHIBITOR MAXIMAL RESPIRATION Maximal 
respiration OCR values of hCMEC/D3 cells were calculated, based on real-time OCR 
measurements, for each inhibitor treatment group. Values from each inhibitor group were 
compared to each other group. All measurements were normalized to 10 µg protein. Each 
point represents a single measurement and error bars represent SEM of n=3 samples. 
Shared letters indicate no significant difference. Absence of a shared letter indicates a 
significant difference between groups. 
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Figure 33: HCMEC/D3 INHIBITOR SPARE RESPIRATORY CAPACITY Spare 
respiratory capacity OCR values of hCMEC/D3 cells were calculated, based on real-time 
OCR measurements, for each inhibitor treatment group. Values from each inhibitor group 
were compared to each other group. All measurements were normalized to 10 µg protein. 
Each point represents a single measurement and error bars represent SEM of n=3 
samples. Shared letters indicate no significant difference. Absence of a shared letter 
indicates a significant difference between groups. 
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Figure 34: HCMEC/D3 INHIBITOR PROTON LEAK Proton leak OCR values of 
hCMEC/D3 cells were calculated, based on real-time OCR measurements, for each 
inhibitor treatment group. Values from each inhibitor group were compared to each other 
group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 35: HCMEC/D3 INHIBITOR NON-MITOCHONDRIAL OCR non-
mitochondrial OCR values of hCMEC/D3 cells were calculated, based on real-time OCR 
measurements, for each inhibitor treatment group. Values from each inhibitor group were 
compared to each other group. All measurements were normalized to 10 µg protein. Each 
point represents a single measurement and error bars represent SEM of n=3 samples. 
Shared letters indicate no significant difference. Absence of a shared letter indicates a 
significant difference between groups. 
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Figure 36: HCMEC/D3 INHIBITOR COMPENSATORY PER Compensatory PER 
values of hCMEC/D3 cells were calculated, based on real-time PER measurements, for 
each inhibitor treatment group. Values from each inhibitor group were compared to each 
other group. All measurements were normalized to 10 µg protein. Each point represents a 
single measurement and error bars represent SEM of n=3 samples. Shared letters indicate 
no significant difference. Absence of a shared letter indicates a significant difference 
between groups. 
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Figure 37: HCMEC/D3 INHIBITOR MITOCHONDRIAL ATP PRODUCTION 
RATES Mitochondrial ATP production rate values of hCMEC/D3 cells were calculated, 
based on real-time OCR measurements, for each inhibitor treatment group. Values from 
each inhibitor group were compared to each other group. All measurements were 
normalized to 10 µg protein. Each point represents a single measurement and error bars 
represent SEM of n=3 samples. Shared letters indicate no significant difference. Absence 
of a shared letter indicates a significant difference between groups. 
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Figure 38: HCMEC/D3 INHIBITOR GLYCOLYTIC ATP PRODUCTION RATES 
Glycolytic ATP production rate values of hCMEC/D3 cells were calculated, based on 
real-time PER measurements, for each inhibitor treatment group. Values from each 
inhibitor group were compared to each other group. All measurements were normalized 
to 10 µg protein. Each point represents a single measurement and error bars represent 
SEM of n=3 samples. Shared letters indicate no significant difference. Absence of a 
shared letter indicates a significant difference between groups. 
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Figure 39: HCMEC/D3 INHIBITOR TOTAL ATP PRODUCTION RATES Total 
ATP production rate values of hCMEC/D3 cells were calculated, by adding 
mitochondrial and glycolytic ATP production rates, for each inhibitor treatment group. 
Values from each inhibitor group were compared to each other group. All measurements 
were normalized to 10 µg protein. Each point represents a single measurement and error 
bars represent SEM of n=3 samples. Shared letters indicate no significant difference. 
Absence of a shared letter indicates a significant difference between groups. 
 
Chapter 8: Discussion 
     Using real-time measurements of OCR and ECAR, the mitochondrial respiration and 
glycolytic rates of hCMEC/D3 human immortalized microvascular endothelial cells were 
able to be quantified, respectively. Using this technology, we were able to reveal many 
insights into brain endothelial cell OCR, PER, and ATP production rates. After 
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characterizing mitochondrial respiration and glycolytic rates, we then tested metabolite 
preference of glucose, glutamine, pyruvate, or a combination of two or three metabolites. 
We were then able to test the metabolic plasticity of hCMEC/D3 cells by utilizing various 
nutrient transport inhibitors. These small molecule inhibitors targeted GLUT1, MCT1, 
MPC, and GLS. Inhibiting these transporters allowed us to observe how hCMEC/D3 cells 
are able to compensate in energy production with the disruption of different metabolic 
pathways. 
     Initial experiments revealed that hCMEC/D3 cells exhibit a metabolism driven 
majorly by glycolysis, as over 96% of protons exported were from glycolysis, via lactate 
production, rather than OXPHOS. This is further supported by results from ATP rate 
assays performed. These assays reveal that hCMEC/D3 cells display an 85.7% glycolytic 
ATP production rate, while mitochondrial ATP production is 14.3%. These results do not 
support our original hypothesis that hCMEC/D3 cells would have a primarily oxidative 
mode of metabolism.  
     There are advantages to a primarily glycolytic metabolism for brain endothelial cells. 
Increased glycolytic rates decreases the production of damaging reactive oxygen species 
(ROS) and also allows unused oxygen to be available in the surrounding tissue [37]. 
Therefore, it is important to reduce the amount of ROS within the CNS to prevent neural 
damage and dysfunction. Lactate produced via glycolysis can also act as a signaling 
molecule for active angiogenesis [79–81]. This can allow a large proportion of the brain 
and CNS to be vascularized to make nutrient, ion, and other molecules easily accessible 
from the blood. A glycolytic metabolism is furthermore said to precondition endothelial 
cells to sprout in avascular and hypoxic environments [82]. Therefore, it can be beneficial 
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for microvascular endothelial cells to express a highly glycolytic metabolic phenotype to 
encourage maximal vessel sprouting within the CNS and provide oxygen, nutrients, and 
other substances for neural function. 
     With the exception of glutamine alone, cells exposed to glucose, pyruvate, a 
combination of glucose and pyruvate or glucose and glutamine, or a combination of 
glutamine and pyruvate, are able to alter glycolytic or OXPHOS rates to maintain the 
total ATP production rate in hCMEC/D3 cells similarly to complete media. This can be 
accomplished by either increasing glycolytic or OXPHOS rates, based on available 
metabolites, to compensate for a loss in ATP production from OXPHOS or glycolytic 
rates, respectively. This supports the hypothesis that cells alter their metabolic phenotype, 
based on available metabolites, to maintain adequate energy production. It shall be noted, 
however, that mitochondrial and glycolytic ATP production rates remained unchanged in 
cells with glucose and pyruvate combined, in comparison to complete media. Therefore, 
pyruvate can act as a major contributor to OXPHOS with glucose present. Interestingly, 
with glucose as the only metabolite, hCMEC/D3 cells exhibit a lower glycolytic ATP 
production rate and higher mitochondrial ATP production rate than those of which are 
subject to a combination of 5.83 mM glucose, 1.5 mM glutamine, and 1 mM pyruvate. 
This suggests that the cells, when glucose is abundant, in comparison to pyruvate and 
glutamine, utilize pyruvate, glutamine, or both, to increase glycolytic ATP production 
rates. With an equal concentration of glucose, glutamine, and pyruvate in a single media, 
hCMEC/D3 cells are able to increase mitochondrial respiration and mitochondrial ATP 
production rates. Glycolysis and glycolytic ATP rates, in contrast, decrease for cells in 
this complete media compared to control media containing 5.83 mM glucose, 1.5 mM 
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glutamine, and 1 mM pyruvate. Although mitochondrial respiration increases, the total 
ATP production rate of cells in this complete media is lower than cells in control media. 
Since OXPHOS produces more ATP molecules, per molecule of glucose, than glycolysis, 
glycolytic and total ATP production rates could be lowered as the total available ATP 
amount within the cells can remain constant. 
     As these studies have shown, hCMEC/D3 cells are highly reliant on glycolysis as a 
mode of energy production. Inhibiting GLUT1, via BAY876, showed to significantly 
decrease glycolytic and total ATP production rates. However, inhibition of MCT1, MPC, 
and GLS had no effect on ATP production.  UK5099, MD1, and BPTES did not affect 
basal respiration or glycolytic rates. However, UK5099, MD1, and BPTES decreased 
maximal respiration and spare respiratory capacity OCR. This suggests that the 
mitochondria of hCMEC/D3 cells are able to adequately fuel basal oxygen consumption, 
even with MPC or GLS inhibited. Pyruvate or glutamine alone can suffice to maintain the 
basal OCR in hCMEC/D3 cells. However, when subjected to FCCP, hCMEC/D3 cells 
are not able to respire as much as the control. This can be due to the lack of one 
metabolite, either pyruvate or glutamine, able to enter the TCA cycle and fuel OXPHOS. 
With one of the two metabolites unable to enter the TCA cycle, maximal respiration and 
spare respiratory capacity is significantly hindered. However, when MPC and GLS are 
inhibited along with GLUT1, these cells are able to maintain maximal respiration OCR. 
This suggests that cells are able to switch from pyruvate and glutamine metabolism to 
fatty acid, amino acid, or both metabolism to fuel OXPHOS. Inhibition of GLUT1 or 
GLS, via BAY876 or BPTES respectively, significantly decreased compensatory 
glycolysis in hCMEC/D3 cells as well. This further supports that glutamine is able to fuel 
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glycolytic rates. However, a combination of BAY876 and MD1 did not show to decrease 
compensatory glycolysis. These inhibition studies support our hypothesis that disruption 
of glucose transport, mitochondrial pyruvate transport, or conversion of glutamine into 
glutamate alter various aspects of glycolytic or mitochondrial energy production. 
Inhibition of lactate transport, however, did not alter cellular metabolism. Exposing cells 
to the small molecule inhibitor MD1 showed similar results of MPC inhibition. This 
suggests that MD1, at 10 µM concentration, acts as an MPC inhibitor rather than a dual 
MCT1 and MCT 4 inhibitor. Given these results, it is possible that inhibiting MCT1 did 
not affect cellular metabolism as cells were able to effectively export lactate at a 
consistent rate via MCT4. 
     These experiments show the rapid metabolic adaptation of hCMEC/D3 cells. These 
cells are able to alter their metabolic phenotype, in a short amount of time, in order to 
compensate for energy demands. Although these cells seem to favor glycolysis, with 
enough substrates to fuel OXPHOS, the cells are able to switch to, and rely on, 
mitochondrial respiration to generate energy. The same phenomenon can be seen with 
nutrient transport inhibition. Although the cells cannot maintain total ATP production, 
when glucose transport is inhibited, hCMEC/D3 cells increase OXPHOS in an attempt to 
meet energy demands. With glucose as an only substrate, hCMEC/D3 cells are able to 
utilize glycolysis while OXPHOS is decreased as a majority of glucose is shunted to 
lactate production. 
     Extracellular flux analysis reveals can reveal many insights of cellular energetic rates. 
There is supporting evidence that shows using this technology can allow quantification of 
glycolytic, OXPHOS, and ATP production rates accurately. Quantifying these rates can 
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reveal the metabolic phenotype and plasticity in various substrate compositions. Further 
analysis can also reveal how much certain metabolic substrates contribute to glycolysis 
and OXPHOS. Such studies have been performed by Mookerjee et al., (2017), providing 
useful calculations and analyses of metabolic substrate contribution to cellular energetics. 
Though this indirect method of measuring cellular energetics is well supported and 
beneficial, it does not provide specific amounts of intracellular metabolites and ATP. In 
order to measure these parameters, mass spectrometry and a fluorescent, or radioactive, 
labeled ATP rate assay can be utilized. These experiments can reveal the intracellular 
amounts of metabolite intermediates and ATP, respectively. 
     Metabolomics is gaining attention in cancer treatment, stem cell biology, and 
immunology. These results can contribute to furthering research in CNS disorder 
treatments. Understanding healthy brain endothelial cell bioenergetics can give 
investigators a platform to begin studying disease-state alterations in brain endothelial 
cellular metabolism. A dysfunctional NVU has shown to be associated with various CNS 
disorders. This dysfunction can be associated with changes in brain endothelial cell 
metabolism. Different disease states can possibly exhibit a specific, altered, metabolic 
phenotype in brain endothelial cells. Targeting altered metabolic pathways in disease-
state brain endothelial cells can provide a non-invasive method of treatment for diseases 
involved with NVU dysfunction. On the contrary, understanding healthy brain 
endothelial cell metabolism can also possibly prevent NVU dysfunction and age-
associate pathologies of the NVU. Incorporating a diet, or developing supplements, that 
support healthy brain endothelial cell metabolism can, in turn, support healthy CNS 
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function. Adequate levels of glucose, glutamine, pyruvate, and other substances in blood 
serum can support healthy brain endothelial cell function, and thus healthy CNS function. 
     Though much was gathered from these studies, there is quite a lot of uncovered 
information regarding the bioenergetics of brain endothelial cells that can explored. 
Future studies can investigate, even further, the roles different metabolites play in 
hCMEC/D3 bioenergetics. Such metabolites can include fatty acids, lactate, various 
amino acids, TCA molecules, and other compositions. Other future studies may involve 
measuring cell bioenergetics in a hypoxic environment or by using a disease-state model 
to measure differences in energy production between healthy and disease-state. Effects of 
simulating blood flow, co-culture with other cells of the NVU, and in vivo studies can 
give insights to bioenergetics of brain endothelial cells in a more physiological 
environment. Metabolic enzyme expression and activity in brain endothelial cells can 
also reveal important information regarding brain endothelial cell bioenergetics. As with 
the effect of metabolites and metabolic pathways, changes in brain endothelial cell 
bioenergetics can very well involve changes in metabolic enzyme expression or activity. 
Given the highly glycolytic nature of these cells, it is possible that major changes would 
involve glycolytic enzymes. This could reveal other targets for diseases involving NVU 
dysfunction or, contrarily, insights to maintaining healthy NVU function. Measuring the 
bioenergetic properties, using extracellular flux analysis, of hCMEC/D3 cells revealed an 
abundance of information regarding brain endothelial cell metabolism. These studies 
provide a glance of brain endothelial cell bioenergetics in vitro and can be referred back 
to in future studies involving brain endothelial cell or NVU metabolism. 
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